nesium (Mg 2ϩ ) is an essential ion to the human body, playing an instrumental role in supporting and sustaining health and life. As the second most abundant intracellular cation after potassium, it is involved in over 600 enzymatic reactions including energy metabolism and protein synthesis. homeostasis in the intestine, kidney, and bone and disturbances which may result in hypomagnesemia.
) is an essential ion to the human body, playing an instrumental role in supporting and sustaining health and life. As the second most abundant intracellular cation after potassium, it is involved in over 600 enzymatic reactions including energy metabolism and protein synthesis. Although Mg 2ϩ availability has been proven to be disturbed during several clinical situations, serum Mg 2ϩ values are not generally determined in patients. This review aims to provide an overview of the function of Mg 2ϩ in human health and disease. In short, Mg 2ϩ plays an important physiological role particularly in the brain, heart, and skeletal muscles. Moreover, Mg 2ϩ supplementation has been shown to be beneficial in treatment of, among others, preeclampsia, migraine, depression, coronary artery disease, and asthma. Over the last decade, several hereditary forms of hypomagnesemia have been deciphered, including mutations in transient receptor potential melastatin type 6 (TRPM6), claudin 16, and cyclin M2 (CNNM2). Recently, mutations in Mg 2ϩ transporter 1 (MagT1) were linked to T-cell deficiency underlining the important role of Mg 2ϩ in cell viability. Moreover, hypomagnesemia can be the consequence of the use of certain types of drugs, such as diuretics, epidermal growth factor receptor inhibitors, calcineurin inhibitors, and proton pump inhibitors. This review provides an extensive and comprehensive overview of Mg 2ϩ research over the last few decades, focusing on the regulation of Mg 2ϩ homeostasis in the intestine, kidney, and bone and disturbances which may result in hypomagnesemia. plays an important role in the physiological function of the brain, heart, and skeletal muscles. Mg 2ϩ has anti-inflammatory properties and acts as Ca 2ϩ antagonist. The United States Food and Nutrition Board recommends a daily intake of 420 mg for men and 320 mg for women (1) . However, recent reports estimate that at least 60% of Americans do not consume the recommended daily amount of Mg 2ϩ (281) . Part of the problem stems from the soil used for agriculture, which is becoming increasingly deficient in essential minerals. Over the last 60 years the Mg 2ϩ content in fruit and vegetables decreased by 20 -30% (570) . Moreover, the Western diet contains more refined grains and processed food. Estimates are that 80 -90% of Mg 2ϩ is lost during food processing. As a result, a significant number of people are Mg 2ϩ deficient, which may comprise up to 60% of critically ill patients (84, 145) . Mg 2ϩ deficiency is commonly determined by measuring total serum Mg 2ϩ concentrations, which ranges between 0.7 and 1.05 mM in a healthy person (323) . However, serum Mg 2ϩ values reflect only 1% of the body Mg 2ϩ content, since most of the body's Mg 2ϩ is stored in bone, muscle, and soft tissues. Therefore, although serum values are within the normal range, the body can be in a severely Mg 2ϩ -depleted state. Consequently, the clinical impact of Mg 2ϩ deficiency may be largely underestimated.
The first use of Mg 2ϩ in human medicine can be traced back to 1697 when Dr. Nehemiah Grew identified magnesium sulfate (MgSO 4 ) as the major ingredient of Epsom salt (195) . Epsom salt was extracted from a well in Epsom, England and was used over the years to treat abdominal pain, constipation, sprains, muscle strains, hyaline membrane disease, and cerebral edema. Subsequently, Mg 2 ] and mercury in 1808 (102) . The role of Mg 2ϩ in the human body emerged once Mg 2ϩ was described in blood plasma by Willey Glover Denis in 1920 (113) . In 1926, Jehan Leroy demonstrated that Mg 2ϩ is essential for life in mice (309) . These findings were trans-lated to humans, and the first report of Mg 2ϩ deficiency in humans was by Arthur Hirschfelder and Victor Haury in 1934 (231) . Since then, Mg 2ϩ has been implicated in and used for treatment of a variety of diseases, including migraines, cardiovascular diseases, and diabetes. Although the importance of Mg 2ϩ is widely acknowledged, serum Mg 2ϩ values are not generally determined in clinical medicine. Therefore, Mg 2ϩ is often referred to as the "forgotten" cation in human health.
This review provides an overview of the role of Mg 2ϩ in human health and disease. Mg 2ϩ has important cellular functions in enzymatic reactions and in the synthesis and structure of proteins and polynucleotides, which are described in section II. The important regulation of Mg 2ϩ homeostasis is discussed in depth in section III. The role of Mg 2ϩ in organ function and related diseases is discussed in section IV. An overview is presented of the most important diseases in which Mg 2ϩ disturbances have been implicated or in which Mg 2ϩ has been considered as a potential treatment. In last part of the review, special attention is awarderd to disturbances of intestinal Mg 2ϩ uptake and renal Mg 2ϩ excretion (sect. V). All together, this review emphasizes the importance of a controlled Mg 2ϩ balance in the human body. Increasing the awareness and understanding of Mg 2ϩ homeostasis may give more clinical attention to the important role of Mg 2ϩ in health and disease.
II. MAGNESIUM IN CELLULAR PHYSIOLOGY
Within the periodic table of elements, Mg has the atomic number 12 and is classed as an alkaline earth element (group 2). Mg occurs in three stable isotopes: 24 Mg, 25 Mg, and 26 Mg. 24 Mg is the most common isotope (78,99%) and has a relative atomic mass of 24.305 Da, a melting point of 648.8°C, and a boiling point of 1,090°C (350) . Mg 2ϩ is highly soluble and the second most abundant cation in seawater (95) . In the dissolved state, Mg 2ϩ has two hydration shells, making its hydrated radius ϳ400 times larger than its dehydrated radius, larger than that of other cations like Na ϩ , K ϩ , and even Ca 2ϩ (95) . Consequently, Mg 2ϩ needs to be dehydrated before passing through channels and transporters, a process that requires a lot of energy. Mg 2ϩ is a powerful Ca 2ϩ antagonist, despite both having similar charge and chemical properties.
Mg
2ϩ is the second most abundant intracellular cation with typical concentrations of ϳ10 -30 mM. However, since most of the intracellular Mg 2ϩ is bound to ribosomes, polynucleotides and ATP, the concentration of freely available Mg 2ϩ falls within the low millimolar range (0.5-1.2 mM) (133). In contrast to other abundant ions, for which cells maintain considerable transmembrane gradients, the free Mg 2ϩ concentrations in the cell and in the extracellular fluid are comparable. Mg 2ϩ is a versatile ion that is involved in practically every major metabolic and biochemical process within the cell. Although it extends beyond the purpose of this review to give a comprehensive overview of all biochemical reactions and structural processes involving Mg 2ϩ , the following paragraphs will highlight the most prominent cellular processes in which Mg 2ϩ is involved.
A. Nucleotide Binding
Mg 2ϩ forms an essential component of the RNA and DNA tertiary structures, as it binds the negatively charged O and N molecules within the polynucleotide chains. Polynucleotide binding is a complex biophysical process that mainly depends on the level of Mg 2ϩ dehydration and the electrostatic potential at the binding site (for extensive review, see Ref. 347 -binding sites, three in the core region around the bend of the L-shaped molecule and two additional sites in the major groove of the anticodon stem (412, 556) . Additionally, there may be a few dozen Mg 2ϩ in close vicinity of tRNA molecules that may bind weakly to the exterior of the structure (347) . Still, the importance of Mg 2ϩ binding for the tRNA tertiary structure has been contested over the years. This discussion was mainly triggered by studies showing the importance of nonspecific diffuse binding of Mg 2ϩ and other divalent and monovalent cations, questioning the specificity of the Mg 2ϩ interactions. However, the role of Mg 2ϩ in RNA structure extends beyond tRNAs. For instance, Mg 2ϩ is also crucial to the interactions that stabilize the pseudoknot conformation (191) , tertiary RNA structures that are present in mRNA, ribosomal RNA, transfer-messenger RNA, catalytic self-splicing RNA, and viral genomic RNA.
In DNA, Mg 2ϩ forms hydrogen bonds with the electronegative elements (O, N) to stabilize the natural DNA conformation, referred to as B-DNA (85, 549) . Moreover, Mg 2ϩ plays a role in the secondary and tertiary structure of DNA by competing with monovalent ions (394) . Mg 2ϩ binds the minor groove of B-DNA structures, thus protecting it. In Mg 2ϩ -deficient conditions, DNA is more accessible to free oxygen radicals and more prone to oxidative stress (406) . However, at higher Mg 2ϩ concentrations, Mg 2ϩ may covalently bind DNA, locally distorting the double helix (22). Therefore, maintaining the cellular Mg 2ϩ concentration within the physiological range is essential for DNA stability.
B. Enzymatic Activity
In medical textbooks and scientific literature, Mg 2ϩ is often described as a cofactor for ϳ300 enzymes. Theodor
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Günther introduced the number 300 as a rough estimate in 1980 and this has been in use ever since (133). However, in the decades after 1980 many new Mg 2ϩ -dependent enzymes have been described, and the number 300 is, therefore, an underestimation. Currently, enzymatic databases list over 600 enzymes for which Mg 2ϩ serves as cofactor, and an additional 200 in which Mg 2ϩ may act as activator (32, 73) . An overview of these Mg 2ϩ -dependent enzymes can be found at MetaCyc (http://www.metacyc.org; Ref. 73) . Many of the enzymes that require Mg 2ϩ as coactivator are vital for life.
Mg
2ϩ is necessary for the proper structure and activity of DNA and RNA polymerases (56, 500). DNA polymerases have two Mg 2ϩ binding sites, which are hypothesized to play a key role in the conformational changes in the polymerase enzyme during the catalytic reaction (56). This model was further enhanced by studies reporting that the release of one of the Mg 2ϩ ions is necessary for opening the catalytic site for new nucleotides (577) . In addition, Mg 2ϩ is an important factor in DNA repair mechanisms within the cell, including nucleotide excision repair (NER), base excision repair (BER), and mismatch repair (MMR). Mg 2ϩ acts as cofactor for almost every enzyme involved in basically every step of NER (68) . In BER, Mg 2ϩ is elemental for the activity of endonucleases, which incise the DNA after DNA damage, and the DNA polymerases and ligases, which repair the gap (41, 473) . The third repair pathway, MMR, is also affected by Mg 2ϩ availability since several enzymes involved require Mg 2ϩ and ATP for activity (33). Other enzymes requiring Mg 2ϩ are topisomerases, helicases, exonucleases, protein kinases, cyclases, and large groups of ATPases, meaning that Mg 2ϩ is an essential component of DNA replication, RNA transcription, amino acid synthesis, and protein formation. Altogether, Mg 2ϩ is a key factor in the maintenance of genomic and genetic stability. The consequences of low Mg 2ϩ availability on the development of cancer is discussed in section IIE1.
2ϩ is also an important regulator of many enzymes involved in glycolysis, because it is a cofactor for adenine nucleotides. Mg-ATP is required for the activity of hexokinase, phosphofructokinase, aldolase, phosphoglycerate kinase, and pyruvate kinase (166, 550) . Consequently, Mg 2ϩ availability is of major importance for glucose metabolism, which may explain its role in diabetes mellitus type 2 (see sect. IVE1).
The role of Mg 2ϩ , however, extends far beyond DNA and protein synthesis, DNA repair, and glycolysis. Since kinases, ATPases, guanylyl cyclases, and adenylyl cyclases all depend on Mg-ATP for proper function, Mg 2ϩ plays a role in virtually every process in the cell.
C. Cellular Mg 2؉ Handling
Since protein and DNA synthesis are highly dependent on intracellular Mg 2ϩ availability, intracellular Mg 2ϩ concentrations are tightly regulated. Over the last 20 years, elucidating the molecular identities of the transporters involved in Mg 2ϩ homeostasis has been the main focus of research within the Mg 2ϩ field. Genetic screenings on human diseases and microarray-based expression studies have resulted in the identification of numerous Mg 2ϩ -transporting proteins (TABLE 1 and FIGURE 1). Although the exact role of many of these proteins needs further investigation, re- 
TRPM7
TRPM7 is a ubiquitously expressed divalent cation channel that is responsible for much of the Mg 2ϩ flux in the cell. TRPM7 activity is generally regarded as a prerequisite for cell viability (360, 455) . However, recent reports with tissue-specific TRPM7 KO mice suggest that TRPM7-deficient T cells are still viable and have normal intracellular Mg 2ϩ concentrations (266) . TRPM7 constitutes a tetrameric channel, where each subunit consists of six transmembrane regions with a pore region between the fifth and sixth transmembrane domain (42). The intracellular COOH terminus contains a kinase domain that regulates autophosphorylation of the channel, although its mechanism is poorly understood, as TRPM7 channel function is not dependent on its kinase activity (504) . Initially, the kinase was reported to exist as separate entity (438) , and indeed, recently it was shown that the kinase is cleaved from TRPM7 by caspase-8, although the exact function of the cleaved kinase remains unknown (115).
MagT1
Originally identified in MDCT cells, Mg 2ϩ transporter 1 (MagT1) has been described as a ubiquitously expressed Mg 2ϩ channel (187) . Survival and growth of TRPM7-defi-FIGURE 1. Magnesium in cellular physiology. Cellular Mg 2ϩ homeostasis is regulated by the combined action of TRPM7, SLC41A1, MagT1, and CNNM3 Mg 2ϩ transporters. MRS2 transporters regulate intramitochondrial Mg 2ϩ concentrations. In the nucleus, Mg 2ϩ is involved in DNA stability and DNA repair and regulates the activity of the DNA and RNA polymerases. Within the cell cytosol, Mg 2ϩ regulates ATP binding, enzymatic activity of more than 600 enzymes, proliferation, and tRNA and mRNA stability. Activation of growth factor receptors, such as the EGFR, will increase Mg 2ϩ uptake and release of membrane-bound Mg 2ϩ resulting in mTOR activation and Ca 2ϩ release from the ER. These mechanisms are essential for cell growth and proliferation. TRPM7, transient receptor potential melastatin type 7; CNNM3, cyclin M3; SLC41A1, solute carrier family 41 type 1; MagT1, magnesium transporter 1; MRS2, mitochondrial RNA splicing 2; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; PI3K, phosphoinositide 3-kinase; mTOR, mammalian target of rapamycin; PLC␥, phospholipase C-␥; PIP 3 , phosphatidylinositol 3,4,5-trisphosphate; IP 3 , inositol trisphosphate.
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cient cells can be partially rescued by MagT1 overexpression (110) . Although identification of MagT1 dates back almost 10 years, the functional characteristics of MagT1 are still undetermined. MagT1 mediates highly specific Mg 2ϩ currents in Xenopus laevis oocytes, but these results could not be reproduced in mammalian cells (187, 589) . Recent studies in T cells suggest that MagT1 mediates a rapid Mg 2ϩ influx upon receptor activation (79, 311) . Since T cells do not require TRPM7 for maintaining normal intracellular Mg 2ϩ concentrations (266) , this suggests that MagT1 has a similar function as TRPM7 in certain cell types.
Extrusion
In 1984, Theodor Gunther et al. (214) proposed that the main route of Mg 2ϩ efflux from the cell is Na ϩ dependent. A large body of evidence obtained in a wide range of cell types supports this notion (reviewed in Ref. 424) . Over the last decades, the mechanism has been further characterized in a variety of cell types, demonstrating inhibition by Na ϩ channel blockers such as amiloride, imipramine, and quinidine. The stoichiometry of this exchange mechanism is still not fully elucidated; Na ϩ -dependent Mg 2ϩ extrusion is activated by cAMP in several cell models and conditions (424) , but Na ϩ -independent Mg 2ϩ extrusion has also been proposed. Ebel et al. (134) reported the presence of a choline-dependent Mg 2ϩ transporter in erythrocytes. However, the molecular identity of this proposed Mg 2ϩ efflux mechanism remains controversial.
SLC41A1
Recent reports by Kolisek and co-workers (288, 289) suggested that solute carrier family 41 member 1 (SLC41A1) functions as a Na ϩ /Mg 2ϩ exchanger with a 2:1 stoichiometry. SLC41A1 contains 11 transmembrane domains and was originally described as a Mg 2ϩ transporter mediating Mg 2ϩ currents in Xenopus laevis oocytes (185) . Although electrophysiological analysis could not confirm these measurements in mammalian cells, Mg 2ϩ efflux studies using mag-fura 2 show Na ϩ -dependent Mg 2ϩ extrusion (251, 289) . Gain-of-function SNPs have been associated with Parkinson's disease, and one mutation in SLC41A1 was identified in a patient with a nephronophthisis-like phenotype (251, 290, 576) . SLC41A1 is part of a larger protein family including two additional members, SLC41A2 and SLC41A3, which are studied less extensive. Although SLC41A2 was initially described as a plasma membrane protein, it has a topology opposite to SLC41A1 (442) . This finding suggests that SLC41A2 might be expressed on the membranes of organelles and may be involved in subcellular Mg 2ϩ transport.
CNNM3
Members of the Cyclin M (CNNM) family have been proposed to function as Mg 2ϩ transporters (184, 545) .
CNNM1 is mainly expressed in brain, CNNM2 expression is high in kidney, and CNNM4 is primarily expressed in intestine (105) . In contrast, CNNM3 has a ubiquitous expression pattern and may play a role in the maintenance of cellular Mg 2ϩ homeostasis. A recent study shows that CNNM3 transports Mg 2ϩ , and its activity is regulated by oncogene PRL2 (217) . The interaction between PRL2 and CNNM3 is essential for Mg 2ϩ influx that drives tumor growth. Therefore, CNNM3 should be considered in future studies on cellular Mg 2ϩ handling in nonpathological conditions.
MRS2
Although most studied in yeast, MRS2 (mitochondrial RNA splicing 2) is considered to be the primary Mg 2ϩ channel on the mitochondrial membrane (592 
Others
In addition to the aforementioned Mg 2ϩ transporters, several other proteins have been proposed to transport Mg 2ϩ . However, these claims are based mainly on overexpression in the Xenopus oocytes model, and functional evidence for these proteins is scarce. For example, the nonimprinted in Prader-Willi/Angelman syndrome (NIPA) family of proteins has been proposed to transport Mg 2ϩ , based on Mg 2ϩ currents in Xenopus laevis oocytes (182), but recent studies indicate that NIPA proteins have a role in bone morphogenetic protein (BMP) signaling (525) . Likewise, Huntingtininteracting protein 14 (HIP14) was thought to mediate Mg 2ϩ fluxes at the Golgi membrane (183) . Now it has become apparent that its main function consists of palmitoyl acyltransferase activity, specifically involved in the palmitoylation of Huntington (129, 582). Therefore, the role of NIPA proteins and HIP14 in Mg 2ϩ transport should be questioned. Additionally, members of the membrane Mg 2ϩ transporter (MMgT) family have been shown to transport divalent cations in Xenopus oocytes (186) . However, as they have only one transmembrane domain after signal peptide cleavage, it is unlikely that they form functional Mg 2ϩ transporters themselves. It is possible that MMgT proteins may form subunits of other Mg 2ϩ channels, and as a consequence, future studies should be directed to the identification of its protein partners.
DE BAAIJ ET AL. (311, 322, 503) . Most recently in a study on T-cell activation, MagT1 channels were shown to mediate Mg 2ϩ influx upon T-cell receptor activation and EGF stimulation (311) . In these T cells, Mg 2ϩ activates phospholipase C-␥ (PLC␥1), resulting in reduced phosphorylation of protein kinase C (PKC) and inositol trisphosphate (IP 3 (79) . These results suggest that the effects seen on PLC␥1 are dependent on general intracellular Mg 2ϩ availability and further question the physiological role of variable fluxes that are proposed in the second messenger theory. Studying Mg 2ϩ dynamics within the cell using fluorescent probes may help to draw definitive conclusions on this matter.
D. Cell Signaling

E. Cell Proliferation
Given its effect on RNA, DNA, and protein synthesis, Mg 2ϩ is an important factor in the control of cell proliferation. Over the last 40 years, the role of Mg 2ϩ in cell cycle control, protein synthesis, and growth factor response has been extensively studied, pioneered by several groundbreaking studies from the group of Harry Rubin (428, 430) . Cell proliferation is largely dependent on protein synthesis, more than DNA or RNA synthesis. Inhibition of protein synthesis directly shuts down DNA synthesis, whereas there is a 2-h delay to achieve the same effect using RNA synthesis inhibitors (279) . Protein synthesis is highly dependent on intracellular Mg 2ϩ concentrations; increasing the Mg 2ϩ content amplifies protein synthesis within 60 min, whereas DNA synthesis is only enhanced after 10 h (429, 514) . Activation of proliferation is initiated by growth factors that increase glucose uptake and protein synthesis within minutes (225) . Interestingly, Mg 2ϩ is tightly regulated during these intracellular processes. Initial studies in cultured cells showed that applying insulin induced 20% higher intracellular Mg 2ϩ concentrations after 16 h (445) . Later studies with EGF using the fluorescent probe mag-fura 2 showed an impressive fourfold increase of intracellular Mg 2ϩ from 0.3 to 1.4 mM after 20 min of epidermal growth factor (EGF) stimulation (199) . The authors state that a rise in Mg 2ϩ precedes DNA synthesis, but coincides with and thus may contribute to increases in protein synthesis. Recent studies identifying the molecular mediators of Mg 2ϩ -dependent cell proliferation have resulted in the membrane, magnesium, mitosis (MMM) model (432) . The MMM model proposes that, upon growth factor binding, Mg 2ϩ enters the cell or is released from phospholipids in the cell membranes (FIGURE 1). Increased cytosolic Mg 2ϩ levels contribute to ribosomal activity and protein synthesis, eventually leading to DNA replication and mitosis. The mammalian target of rapamycin (mTOR) complex is a critical component of the MMM model, as it is the master regulator of cell cycle progression and proliferation (551) . Growth factors binding to their receptors leads to phosphoinositide 3-kinase (PI3K) phosphorylation, which activates the mTOR complex (431, 548) . Activation of mTOR is MgATP 2Ϫ dependent, and ATP has been suggested as the main regulator of mTOR activity. However, ATP levels do not change upon growth factor stimulation, whereas Mg 2ϩ levels do (445, 537) . Therefore, the MMM model proposes Mg 2ϩ as the primary regulator of mTOR dynamics and cell proliferation.
Cancer
Tumor cells contain high concentrations of intracellular Mg 2ϩ (508) . In a mammary tumor cell line, Mg 2ϩ can be transported into the cell even when extracellular Mg 2ϩ concentrations were below physiological levels (203, 264, 566) . Mg 2ϩ uptake via divalent cation channel TRPM7 has been suggested to stimulate tumor cell proliferation (203, 264) . TRPM7 expression is upregulated in hepatoma, pancreatic adenocarcinoma, gastric cancer, and breast cancer tissue (203, 278, 346, 581) . Although TRPM7 has been primarily described as a Mg 2ϩ channel, it is also permeable for other divalent cations (349) . Given the involvement of Mg 2ϩ in cell proliferation, the influx of Mg 2ϩ via TRPM7 has been proposed as the main regulator of tumor growth. However, recent studies using prostate cancer cells suggest that TRPM7-mediated Ca 2ϩ uptake may also play an important role in tumor growth (501 intake and colon cancer risk (160, 302, 534) . In addition, in a study with 1,200 lung cancer patients and a similar number of controls, low dietary Mg 2ϩ intake was associated with reduced lung cancer risk (326) . However, these results could not be reproduced in other patient cohorts (325, 502) .
III. REGULATION OF MAGNESIUM HOMEOSTASIS
Mg 2ϩ serum concentrations range between 0.7 and 1.1 mM in healthy people (323) . To maintain constant plasma Mg 2ϩ levels, the United States Food and Nutrition Board recommends a daily Mg 2ϩ intake of 420 mg for men and 320 mg for women (1) . Mg 2ϩ homeostasis depends on the collaborative actions of the intestine, responsible for Mg 2ϩ uptake from food, the bone, which stores Mg 2ϩ in its hydroxy-apatite form, and the kidneys, regulating urinary Mg 2ϩ excretion (FIGURE 2).
A. Magnesium in Intestine
Given a daily Mg 2ϩ intake of 370 mg, ϳ30 -50% is absorbed in the intestine, resulting in a net uptake of Ϯ100 mg. However, if Mg 2ϩ intake is low, early reports suggest that up to 80% of dietary Mg 2ϩ can be absorbed (189) . Mg 2ϩ absorption in the gut depends on two separate pathways; paracellular transport is responsible for bulk Mg 2ϩ absorption and takes place mostly in the small intestine, whereas fine-tuning occurs in the cecum and colon via transcellular transport (FIGURE 3). In spite of this, the intestine seems to have a limited role in regulation of the Mg 2ϩ balance. In contrast to other minerals, intestinal Mg 2ϩ absorption is poorly regulated and depends mainly on Mg 2ϩ intake (216, 461) . Thus the kidneys presumably primarily regulate the maintainance of Mg 2ϩ homeostasis.
Small intestine
Mg 2ϩ absorption in the small intestine is hypothesized to be exclusively of a paracellular nature, since Mg 2ϩ absorption FIGURE 2. Magnesium homeostasis. Panels represent the daily amount of Mg 2ϩ intake and excretion. Daily the intestines absorb ϳ120 mg and secrete 20 mg of Mg 2ϩ , resulting in a net absorption of 100 mg. In the kidney daily ϳ2,400 mg Mg 2ϩ is filtered by the glomerulus, of which 2,300 mg is reabsorbed along the kidney tubule. This results in a net excretion of 100 mg, which matches the intestinal absorption. Bone and muscle provide the most important Mg 2ϩ stores.
in this region of the intestine correlates linearly to luminal Mg 2ϩ concentrations (273, 409) . Moreover, the epithelial Mg 2ϩ channel TRPM6 is not expressed in the small intestine (196 
Large intestine
Mg 2ϩ absorption in cecum and colon is thought to be transcellular of nature and is mediated by TRPM6 and TRPM7 on the luminal side of the enterocyte (FIGURE 3). Intestinal expression of TRPM6 is located in cecum and colon (196, 300) . In a study with rat colon epithelium, 37% of Mg 2ϩ was transported transcellularly (272) . This suggests signif- (196, 272) . It has been suggested that the basolateral Mg 2ϩ extrusion mechanism of the enterocyte is coupled to the Na ϩ gradient (424) . Indeed, the results of a recent study using CNNM4 KO mice suggest that CNNM4 may act as a Na ϩ /Mg 2ϩ exchanger at the basolateral membrane of enterocytes (575) . CNNM4 KO mice suffer from hypomagnesemia, and functional analysis using Magnesium Green showed that CNNM4 overexpression increased Mg 2ϩ efflux in HEK293 cells. However, patients with CNNM4 mutations do not suffer from hypomagnesemia (387, 402) .
B. Magnesium in Bone
Approximately 50 -60% of the total body Mg 2ϩ content is stored in bone. Serum Mg 2ϩ concentrations are closely related to bone metabolism; bone surface Mg 2ϩ is continuously exchanged with blood Mg 2ϩ (14) . In bone, Mg 2ϩ ions bind at the surface of the hydroxyapatite crystals. Mg 2ϩ increases the solubility of P i and Ca 2ϩ hydroxyapatite and thereby acts on the crystal size and formation (443) . Mg 2ϩ induces osteoblast proliferation; therefore, Mg 2ϩ deficiency results in decreased bone formation (320) (FIGURE 4) Mg 2ϩ -deficient rats have reduced osteoblast numbers and decreased bone mass (434) . Additionally, Mg 2ϩ deficiency increases the secretion of proinflammatory cytokines such as tumor necrosis factor (TNF)-␣, interleukin (IL)-1␤, and substance P (434, 552) , all of which have been implicated in increased osteoclastic bone resorption (280) . These effects may be further enhanced by reduced parathyroid hormone (PTH) and 1,25(OH) 2 D 3 levels, which are often associated with hypomagnesemia (435) . Interestingly, Mg 2ϩ -deficient rats have reduced chondrocyte column formation, which is associated with reduced SRY (sex determining region Y)-box 9 (SOX9) expression (200) (FIGURE 4 ). SOX9 is a key transcription factor in chondrogenesis. In a recent gene expression study in the Mg 2ϩ -transporting segment of the kidney, SOX9 mRNA was the most increased in the lowMg 2ϩ diet group (104) . These findings suggest that SOX9 is an important transcription factor for bone and kidney Mg 2ϩ homeostasis.
C. Magnesium in Kidney
Approximately 2,400 mg of Mg 2ϩ is filtered by the glomeruli on a daily basis. The nephron recovers 95-99% of this; the remaining 100 mg leaves the body via the urine (FIGURE 2).
Proximal tubule
The mechanisms of proximal tubule (PT) Mg 2ϩ reabsorption are poorly understood, but early micropuncture studies showed that ϳ10 -25% of Mg 2ϩ is reabsorbed by the proximal convoluted tubule segment of the nephron (304, 411) . In the glomeruli, 70% of the serum Mg 2ϩ is freely filterable, suggesting that the concentration in the glomerular filtrates and thus at the start of the PT ranges between 0.5-0.7 mM. The transepithelial potential difference ranges from slightly lumen negative (Ϫ6 mV) in the early parts of the PT to positive (3 mV) in later parts (287) . Micropuncture studies have shown that a 1.9 ratio between the concentrations of Mg 2ϩ in the tubular fluid and the interstitial fluid is necessary to initiate Mg 2ϩ transport (304) . This finding could be explained by the poor tight junction permeability for Mg 2ϩ in PT. As a result, water uptake via aquaporin 1 (AQP1) precedes Mg 2ϩ reabsorption (410) (FIGURE 5). Consequently, Mg 2ϩ reabsorption mainly occurs in the late parts of the PT, where the transepithelial chemical Mg 2ϩ gradient is sufficient to favor Mg 2ϩ transport. PT Mg 2ϩ reabsorption is generally considered to be a passive paracellular process, but there might be some transcellular Mg 2ϩ transport via a poorly characterized amiloride-sensitive mechanism (254) . In both cases, sufficient Na ϩ transport is required to drive water transport that is a prerequisite for Mg 2ϩ reabsorption. Hormonal effects on Na ϩ reabsorption in the PT will therefore also affect Mg 2ϩ reabsorption in this segment. However, disturbances of proximal tubular FIGURE 5. Magnesium reabsorption in the kidney. The glomerulus filters the blood, and along the nephron 95% is reabsorbed. In the late proximal tubule (PT), Na 
Mg
2ϩ reabsorption generally do not result in clinical symptoms, since more distal segments will compensate for reduced Mg 2ϩ uptake in PT.
Thick ascending limb of Henle's loop
Whereas most electrolytes are majorly transported in the PT, the thick ascending limb of Henle's loop (TAL) is the main location for Mg 2ϩ reabsorption (236, 299, 420) . Due to the unique properaties of this segment, ϳ50 -70% of filtered Mg 2ϩ is reabsorbed here. Most of the Mg 2ϩ is reabsorbed by the cortical part of the TAL, since medullary Mg 2ϩ reabsorption is negligible (468) . Paracellular bulk Mg 2ϩ transport is dependent on the lumen-positive transepithelial voltage (ϩ10 mV) that is determined by the activity of the Na ϩ -K ϩ -2Cl Ϫ cotransporter (NKCC2) and the subsequent secretion of K ϩ at the apical membrane (192) . Inhibition of NKCC2 by furosemide diuretics therefore decreases TAL Mg 2ϩ reabsorption (see sect. VB3). Further contributors to the transepithelial membrane voltage are K ϩ secretion via renal outer medullary potassium channel (ROMK) and paracellular backflux of Na ϩ ions as a result of decreasing luminal Na ϩ concentrations (329).
The reabsorption of Mg 2ϩ in the TAL follows the paracellular pathway and therefore depends on the tight junction permeability (FIGURE 5). Tight junctions form a physical and chemical barrier between the epithelial cells. Their major components are proteins of the claudin family. Currently, 26 claudins have been described in humans (209) . Tight junction permeability is determined by the individual claudins in each tight junction complex. TAL tubuli are known to express claudins 3, 10, 11, 14, 16, and 19. Claudins 16 and 19 are considered to be the main claudins influencing Mg 2ϩ permeability, since mutations in these proteins result in renal Mg 2ϩ wasting (293) (FIGURE 5).
However, the role of claudin 16 in Mg 2ϩ reabsorption is controversial. Claudin 16 was initially considered to act as a paracellular Mg 2ϩ channel, but this hypothesis has not been unequivocally confirmed (207, 245) . Reports using the claudin 16 knockdown (KD) mouse model and the LLC-PK 1 cell model suggest that claudin 16 increases Na ϩ permeability (227, 245, 466) . This would imply that claudin 16 is mainly involved in the regulation of the transepithelial voltage gradient by controlling the paracellular Na ϩ backleak. In MDCK-C7 cells overexpressing claudin 16, Na ϩ permeability yet remained stable, whereas Mg 2ϩ permeability increased significantly (207) . Claudin 16 KD mice demonstrate a twofold lower permeability ratio for Na ϩ over Cl Ϫ without a change in paracellular conductance. Consequently, the transepithelial voltage collapsed, reducing the driving force for Mg 2ϩ reabsorption in TAL (466) .
Claudin 19 has been studied less extensively, but has been suggested to increase the tight junction barrier function (24). The claudin 19 KD mouse exhibits highly increased
, and Ca 2ϩ , but Mg 2ϩ is the only electrolyte altered at the serum level (246) . The discrepancy between studies with claudin 16 and claudin 19 isoforms might be explained by their interdependence in forming functional tight junction barriers (246, 247 , it would be interesting to address the effect of elevated serum Mg 2ϩ levels on claudin 14 expression in future studies.
Recently, claudin 10 has been identified as an important factor in cation selectivity in TAL, as demonstrated in a mouse model where claudin 10 was deleted specifically in this segment (57). Claudin 10 TAL-KO mice show hypermagnesemia, nephrocalcinosis, and impaired paracellular Na ϩ permeability. In the absence of claudin 10, TAL tight junctions became more permeable to Ca 2ϩ and Mg 2ϩ and the transepithelial voltage increased. These results are in line with in vitro studies overexpressing claudin 10b, suggesting that this splice variant is mainly expressed in TAL (57, 208).
Distal convoluted tubule
The distal convoluted tubule (DCT) determines the final urinary Mg 2ϩ concentration, since no reabsorption of Mg 2ϩ takes place beyond this segment. Approximately 10% of the total Mg 2ϩ is reabsorbed by tightly regulated transcellular transport mechanisms (64). DCT cells form a high-resistance epithelium with a lumen-negative voltage of approximately Ϫ5 mV (192, 571) . In DCT, TRPM6 divalent cation channels mediate luminal Mg 2ϩ uptake (234, 235) (FIGURE 5). Within the kidney, TRPM6 is specifically expressed in DCT, and its activity is regulated by intracellular Mg 2ϩ (540) . TRPM6 contains six transmembrane spanning domains with a pore region between the fifth and sixth segment and a large kinase domain fused to the channel's intracellular COOH terminus. TRPM6 may function in homo-and heteromeric tetramers with TRPM7, al-
though there is some controversy about the necessity of TRPM7 for TRPM6 function (314, 588) .
TRPM6 is regulated by numerous factors at the level of transcription, plasma membrane availability, and activity (69) . EGF and insulin act on TRPM6 by a PI3K-Akt-Rac1 dependent mechanism, increasing the insertion of TRPM6 in the membrane (361, 515) (FIGURE 5). Insulin may directly affect TRPM6 activity through cylin-dependent kinase 5 (cdk5)-dependent phosphorylation of the channel. Patients with reduced EGFR or insulin receptor (IR) activity are therefore more susceptible to hypomagnesemia (361, 459) . Additionally, estrogens increase TRPM6 mRNA expression (196) . Over the last decade, several important interactors of TRPM6, including receptor for activated C-kinase 1 (RACK1) and prohibitin2 (PHB2/REA), have been identified (70, 71) . RACK1 interacts with the a-kinase domain of TRPM6 in the autophosphorylated state, thereby reducing TRPM6 activity (70) . Other modulators of TRPM6 activity include dietary Mg 2ϩ , pH, and ATP (516). Interestingly, acidification-induced current potentiation is dependent on residues p.Glu1024 and p.Glu1029, which also determine the pore selectivity for Mg 2ϩ (313, 367) . Moreover, recent findings indicate that TRPM6 is inhibited by low concentrations of intracellular ATP (IC 50 29 M), questioning the physiological activity of monomeric TRPM6 channels (588) . Extracellular ATP also inhibits TRPM6 activity via the purinergic receptor P2X4 (103).
A chemical gradient for Mg 2ϩ entry in DCT cells is almost absent. The luminal Mg 2ϩ concentrations vary between 0.2 and 0.7 mM, and the intracellular Mg 2ϩ levels are typically in the range of 0.5-1 mM. Therefore, luminal Mg 2ϩ entry is purely dependent on the negative membrane potential in the DCT cell. Luminal K ϩ channels are indispensable for maintaining the necessary driving force for Mg 2ϩ uptake. The voltage-gated K ϩ channel Kv1.1 has been suggested to provide efflux K ϩ currents resulting in hyperpolarization of the luminal membrane, although expression levels in the DCT are limited (104, 176) . To prevent Mg 2ϩ overload and hyperpolarization of the luminal membrane, intracellular Mg 2ϩ blocks Kv1.1 (179) . Interestingly, recent studies suggest that other potassium channels in the luminal membrane of DCT cells may have comparable roles. ROMK is prominently expressed in DCT, and its expression in this segment is regulated by dietary Mg 2ϩ (104, 572) . Similar to Kv1.1, intracellular Mg 2ϩ blocks ROMK currents, suggesting a regulatory function on Mg 2ϩ homeostasis (578). Moreover, indirect inhibition of ROMK by aldosterone or eptihelial Na ϩ channel (ENaC) blockers represent the only effective approach to prevent renal Mg 2ϩ wasting in most clinical situations (140) .
Several proteins have been proposed to mediate Mg 2ϩ extrusion to the bloodstream, but general consensus of the extrusion mechanism has not been reached (424) . Due to the absence of a representative DCT cell model, the properties of Mg 2ϩ extrusion have not been elucidated. Nevertheless, over the last decade several groups claimed to have identified Mg 2ϩ extrusion proteins. Originally described in 2002, cyclin M2 (CNNM2, previously known as ACDP2) is exclusively expressed at the basolateral membrane of DCT and CNT cells within the kidney (105, 497, 545) . Moreover, expression of CNNM2 is sensitive to dietary Mg 2ϩ availability (104, 497) . CNNM2 was initially depicted as Mg 2ϩ transporter, since overexpression in Xenopus laevis oocytes allows uptake of a variety of divalent cations, with highest affinity for Mg 2ϩ (184) . However, these results could not be confirmed in mammalian cell lines (497) . Alternatively, a Mg 2ϩ -sensing function has been proposed, since CNNM2 harbors a Mg-ATP binding site in its cystathionine-␤-synthase (CBS) domains (105 Recently mutations in the SLC41A1 Mg 2ϩ transporter were described to cause a nephronophthisis-like phenotype (251) . Immunohistological studies showed expression in DCT, but the stainings were not conclusive about the subcellular localization (apical or basolateral) of SLC41A1 proteins (251) . By the use of Mag-Fura, SLC41A1 was demonstrated to increase both Mg 2ϩ absorption and Mg 2ϩ extrusion (251, 289 
IV. MAGNESIUM IN PHYSIOLOGY AND PATHOPHYSIOLOGY
The human body contains ϳ24g Mg 2ϩ , of which 99% is stored in bone, muscle, and other soft tissues. Mg 2ϩ is crit-
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ical to the function of basically every organ in the human body. Moreover, Mg 2ϩ deficiency is associated with a wide range of diseases, and as a result Mg 2ϩ supplementation is considered as potential treatment in many of them (TABLE 2) . This part of the review focuses on the organ-specific functions of Mg 2ϩ and provides an overview of all major diseases in which Mg 2ϩ may play a role.
A. Magnesium in Brain
Low serum Mg 2ϩ values are associated with a wide range of neurological diseases such as migraine, depression, and epilepsy. Neuronal Mg 2ϩ concentrations are of major importance in the regulation of N-methyl-D-aspartate (NMDA) receptor excitability. NMDA receptors are essential for excitatory synaptic transmission, neuronal plasticity, and excitotoxicity and therefore play an important role in developmental plasticity, learning, and memory (384) . NMDA receptors are activated upon glutamate binding and mediate the influx of Ca 2ϩ and Na ϩ ions and the efflux of K ϩ ions. Every NMDA receptor consists of four subunits, each with different biochemical properties (97) . In Mg 2ϩ deficiency, NMDA receptors become hyperexcitable, which can be explained by inhibitory function of extracellular Mg 2ϩ on the receptors (335, 372) (FIGURE 6). Glutamate from the presynaptic neuron will bind both the ionotropic 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA) and NMDA receptors on the postsynaptic neuron. At a normal membrane potential of Ϫ70 mV, Mg 2ϩ ions block NMDA receptors. Therefore, only AMPA receptors will be activated and consequently facilitate an influx of cations. Only when the membrane potential rises above Ϫ60 mV the Mg 2ϩ block is relieved and NMDA receptors are opened upon glutamate binding. The unlocking mechanism consists of a slow and a fast component, which depend on the relative expression of subunits that compose the channel (87, 536) . Upon reduced extracellular Mg 2ϩ concentrations, less NMDA channels will be blocked, and more NMDA channels can be opened at relatively low membrane potentials (351) . This increased excitatory postsynaptic potential causes hyperexcitability of the neurons.
In the adult brain, this process is further amplified by the action of inhibitory ␥-aminobutyric acid (GABA) receptors, whose function is also regulated by Mg 2ϩ . GABA A receptors are ionotropic anion channels that open upon GABA binding and facilitate Cl Ϫ influx (250) . Since the equilibrium potential of Cl Ϫ is 10 -20 mV lower than the membrane potential, this influx contributes to hyperpolarization of the neuronal cells. Extracellular Mg 2ϩ stimulates GABA A receptors resulting in hyperpolarized neuronal cells (353) . When Mg 2ϩ concentrations in the central nervous system (CNS) are low, GABA A receptors are less stimulated. Consequently, the membrane potential will be higher, This table summarizes all diseases in which Mg 2ϩ has been considered as treatment by the official American guidelines. Moreover, it lists all large-scale clinical studies and meta-analyses of small-scale clinical studies by the Cochrane collaboration. RR, risk ratio; OR, odds ratio; CI, confidence interval; DBP, diastolic blood pressure; GS, Glasgow score. Reference numbers are given in parentheses. *In addition to standard nimodipine treatment.
ϩ Early mortality in patients treated with Ͻ75 mmol of magnesium compared with placebo groups.
which in turn relieves the Mg 2ϩ block of the NMDA receptor and contributes to hyperexcitability of the neurons.
The final mechanism contributing to the hyperexcitability of NMDA-receptor rich neurons is inhibiting glutamate release from the presynaptic neuron. Release of glutamate can be inhibited by high extracellular Mg 2ϩ concentrations (257, 318, 486) . Although the exact mechanism by which Mg 2ϩ reduces glutamate release is still unknown, it could be related to the inhibition of voltage-gated Ca 2ϩ channels, as glutamate release is triggered by an influx of Ca 2ϩ after an action potential (364) .
As a result of the described mechanisms, low extracellular Mg 2ϩ levels in the CNS contribute to the hyperexcitability of NDMA receptor. The excessive intracellular Ca 2ϩ in the neurons may lead to the production of toxic reactive oxygen species (ROS) and eventually to neuronal cell death.
In addition to increasing the hyperexcitability of excitatory neuronal pathways, Mg 2ϩ has an important role in the regulation of oxidative stress and the release of neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P. CGRP is secreted from sensory neurons and has a vasodilatory effect (48). Mg 2ϩ may increase CGRP expression and secretion, as has been shown in women with preeclampsia (26, 151), although an opposite effect was reported in women with Raynaud's phenomenon (359) . Mg 2ϩ deficiency increases the release of substance P, which is a neuorinflammatory tachykinin (554) , stimulating the FIGURE 6. Magnesium in brain. Mg 2ϩ is an important regulator of glutamate signaling in the brain. Upon glutamate release, glutamate binds NMDAR and AMPAR in the postsynaptic neuron. Mg 2ϩ blocks the NMDAR at membrane potentials less than Ϫ60 mV. Therefore, AMPAR needs to depolarize the cell membrane before NMDAR will be activated. Moreover, Mg 2ϩ stimulates GABA A R and thereby strongly influences the membrane potential of the postsynaptic neuron. In the presynpatic neuron, Mg 2ϩ inhibits glutamate release by antagonizing calcium. Moreover, Mg 2ϩ increases the expression and secretion of CGRP and inhibits the production of NO and the release of SP. Inset: current-voltage curve of NMDAR current. Mg 2ϩ blocks the NMDAR receptor at voltages lower than Ϫ60 mV. NMDAR, N-methyl-D-aspartate receptor; AMPAR, ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; GABA A R, ␥-aminobutyric acid receptor; CGRP, calcitonin gene-related peptide; NO, nitric oxide; SP, substance P; IL-1␤, interleukin-1␤; TNF-␣, tumor necrosis factor-␣.
secretion of inflammatory mediators such as IL-1, -2, -4, -5, -10, -12, and -13 as well as TNF-␣ (552, 554) . Moreover, Mg 2ϩ enhances the activity of nitric oxide synthases (NOS) through a NMDA receptor-dependent mechanism (80, 392) . Nitric oxide (NO) has multiple functions in the brain including vasodilation, regulation of gene transcription, channel activity, and neurotransmitter release (493) . Altogether, the role of Mg 2ϩ in the regulation of neuropeptide release may have serious consequences in neuronal disease.
Migraine
Migraine has been linked to low levels of magnesium in serum and cerebrospinal fluid (CSF) (414, 457) . Migraine headaches are the consequence of cortical spreading depression (CSD), which consists of an intense membrane depolarization and repolarization in neurons and glial cells (308, 388) . CSD can be evoked by NMDA receptor activation (181) . Therefore, patients with an increase in neuronal excitability due to low CSF Mg 2ϩ levels are more susceptible to migraine attacks. Moreover, patients suffering from migraine are often hypotensive during attacks (462) , which can be explained by increased NO levels. NO is an important vasodilator and modulator of brain blood flow (376) . As an inhibitor of NO production, reduced Mg 2ϩ values may result in decreased NO levels (80, 392) .
The first reports of Mg 2ϩ treatment for migraine patients appeared in the 1960s and 1970s (542) , and since then the pharmacological role of Mg 2ϩ has been slowly recognized. Although presently the effectiveness of Mg 2ϩ treatment for the majority of patients is still debated (334, 386) , Mg 2ϩ is a second line drug for migraine patients (148, 237) . Over the last decades several double-blind placebo-controlled randomized trials have provided evidence for a beneficial effect of oral Mg 2ϩ supplementation on the number of migraine attacks (294, 393, 507) as well as the intensity of the pain during these attacks (149, 294 in treating depression and their results are contradictory. In a randomized trial examining depressed elderly patients with diabetes mellitus type 2 and hypomagnesemia, Mg 2ϩ supplementation was as effective as standard imipramine treatment (37). However, this study lacked a placebo control group. Moreover, it should be noted that imipramine therapy is nowadays largely replaced by selective serotonin reuptake inhibitors (SSRI). Another limit of the studies is the small sample population (23 patients). Therefore, large-scale studies are necessary to delineate a role of Mg 2ϩ in the treatment and prevention of depression.
Epilepsy
Seizures are often associated with genetic and acquired forms of hypomagnesemia (see sect. V). Many studies have found that patients suffering from epilepsy display lower blood Mg 2ϩ values (212, 375, 482) . The link between Mg 2ϩ status and the development of seizures may be explained by the role of Mg 2ϩ in NMDA receptor blockade. Most studies addressing this issue show a small but significant decrease in CSF Mg 2ϩ levels in epilepsy patients (492) . In eclampsia patients, Mg 2ϩ has proven to be successful in reducing the risk of recurrent convulsions (198) . For other types of seizures, the evidence is less conclusive. In 1933 the first report of Mg 2ϩ infusions in eight status epilepticus patients, a life-threatening form of epilepsy in which patients suffer from continuous seizures without regaining consciousness, was successful in all cases (496) . However, modern reports of Mg 2ϩ infusion treatment of status epilepticus patients have more variable outcomes and are not as conclusive (159, 383) . Mg 2ϩ infusions are therefore considered a second line of treatment, when anti-epileptic drugs and anesthetics have proven to be unsuccessful. Absence of large-scale randomized double blind placebo-controlled tri-
als obstructs the implementation of Mg 2ϩ as general antiepileptic treatment (9).
Stroke
Stroke is one of the major causes of death in the Western society and has been associated with a drop in serum Mg 2ϩ levels (19). There may be multiple roles for Mg 2ϩ in the etiology of stroke. Low serum Mg 2ϩ levels increase NMDA receptor activity and thus more glutamate and Ca 2ϩ influx. Excessive Ca 2ϩ and glutamate influx via the NMDA receptor may be the basis of excitotoxicity during stroke (137). Since clinical trials with NMDA receptor antagonists have proven to be unsuccessful in treatment of stroke (256), it is, however, unlikely that NMDA receptor blockade alone can fully explain the role of Mg 2ϩ in the development and onset of stroke. Mg 2ϩ also blocks other voltage-gated Ca 2ϩ channels that may be involved in Ca 2ϩ cytotoxicity. Additionally, Mg 2ϩ has a vasodilatory effect, which may be beneficial for patients suffering from ischemic stroke. Although more than 100 neuroprotective agents were tested in animals, not a single agent has been proven successful in a phase 3 clinical trial (111) . After several pilot studies showed beneficial effects of Mg 2ϩ on clinical outcome parameters, two large randomized controlled trials have been performed to determine the role of Mg 2ϩ administration in stroke treatment (355, 356, 449) . The Intravenous Magnesium Efficacy in Stroke Trial (IMAGES) enrolled over 2,500 stroke patients and gave a 16 mmol MgSO 4 bolus injection within 12 h of a stroke, followed by a maintenance dose of 65 mmol over 24 h. No beneficial effects were reported on the primary outcome, death and disability at 3 mo [odds ratio (OR) 0.95, 95% CI 0.80 -1.13]. However, in a subgroup of patients treated within the first 3 h (3.3% of the cohort), a favorable death or disability outcome of 0.66 (95% CI 0.25-1.70) was reported (356) . Since animal studies indicate that Mg 2ϩ treatment is only successful when applied within 3 h of the onset of the stroke (579), a largescale follow-up randomized controlled trial is currently running which aims to treat patients with Mg 2ϩ within the first hours after stroke in a prehospital and emergency department setting. Although the trial is still running, first reports indicate that they have succeeded in including 72% of ϳ1,000 patients within the first hour (448) . Final results from this FAST-MAG study will help determine the efficiency of Mg 2ϩ treatment for stroke patients.
Approximately 5% of all strokes are caused by subarachnoid hemorrhage (SAH) that results from ruptured aneurysms. Delayed cerebral ischemia (DCI) is the major cause of death and disability in patients that survive the first 24 h (126) . Interestingly, patients with SAH often present with hypomagnesemia (531, 532) . Vasoconstriction is the main cause of DCI, and this may be enhanced when the patient is Mg 2ϩ deficient. Over the last decade, several clinical trials have examined the addition of Mg 2ϩ administration to the standard nimodipine treatment (358, 533, 555, 568) (124) . Overall, these studies suggest that intravenous Mg 2ϩ treatment does not improve clinical outcome after aneurysmal subarachnoid hemorrhage.
Brain injury
Mg
2ϩ deficiency is regularly found in patients with traumatic brain injury (TBI) and spinal cord injury (SCI) (81, 268) . Reduced CSF Mg 2ϩ levels increase oxidative stress (ROS, NO) and lipid peroxidation, which both contribute to the severity of TBI (77, 416) . Additionally, it has been proposed that Mg 2ϩ deficiency increases the release of substance P in TBI, resulting in neuronal cell death and edema (539) . In animal experiments, Mg 2ϩ improved sensorimotor/motor function as well as cognitive function (233) . In a small study of 30 TBI patients, Mg 2ϩ supplementation improved patient outcomes as measured by the Glasgow outcome scale (OR 4.13; 95% CI 1.39 -12.27) (116) . A large phase 3 randomized placebo-controlled clinical trial tested the effect of two doses of Mg 2ϩ treatment on 6 mo mortality, seizures, functional measures, and neuropsychological tests in 500 TBI patients. Surprisingly, patients receiving Mg 2ϩ treatment did significantly perform worse on the primary outcome than control patients (48 vs. 54; 95% CI Ϫ10.5 to Ϫ2), suggesting an adverse effect of Mg 2ϩ (511) . A meta-analysis on all clinical trials with TBI patients confirmed that there is no evidence for a neuroprotective role of Mg 2ϩ in TBI (25). This demonstrates again the difficulties in translating the results obtained in animal studies to the clinic (111).
Parkinson's disease
Parkinson's disease is characterized by a loss of dopaminergic neurons. Parkinson's patients have low Mg 2ϩ concentrations in cortex, white matter, basal ganglia, and brain stem (580) . Interestingly, rats with chronic low Mg 2ϩ intake exhibit a significant loss of dopaminergic neurons (381) . In vitro experiments often use differentiated PC12 cells and 1-methyl-4-phenylpyridium ion (MPP ϩ ) to model Parkinson's disease at the cellular level. In this experimental (475) . Moreover, Mg 2ϩ transporter SLC41A1 is located on the PARK16 locus that is associated with Parkinson's disease (576) . Recent characterization of the SLC41A1-pA350V single nucleotide polymorphism (SNP) linked to Parkinson's disease evidenced a gain-of-function effect (290) . These studies suggest that Mg 2ϩ supplementation may be beneficial for patients suffering from Parkinson's disease.
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model, mitochondrial Mg 2ϩ concentrations were decreased as was demonstrated using the mitochondrial KMG-301 fluorescent Mg 2ϩ probe
Other brain pathologies
Low serum Mg 2ϩ levels have also been associated with a wide range of neurological pathologies including schizophrenia, bipolar disorder, neuroses, addiction, stress, and Alzheimer's disease (538) . Although this suggests that Mg 2ϩ deficiency plays a role in the etiology of these pathologies, all reports to date are of an epidemiological nature. There are currently no reports of clinical trials examining the effect of Mg 2ϩ supplementation on the disease outcome of these diseases.
B. Magnesium in Lung
Dietary Mg 2ϩ intake has been repeatedly associated with lung function, as assessed by forced expiratory volume (FEV) and forced vital capacity (FVC) (60, 174) . Lung Mg 2ϩ research suffers from a lack of fundamental studies. As a result, the mechanisms that explain the role of Mg 2ϩ in lung function are poorly understood, and hypotheses are mainly based on studies in other cell types and organs. Nevertheless, the role of Mg 2ϩ in lung function may be explained at three levels: 1) Mg 2ϩ has a strong vasodilator and bronchodilator effect; 2) Mg 2ϩ regulates the release of acetylcholine (ACh) and histamine; and 3) Mg 2ϩ acts as anti-inflammatory agent (FIGURE 7) .
From studies on coronary artery related diseases, it is known that Mg 2ϩ has a vasodilatory effect (512, 513) . Like many vasodilators, Mg 2ϩ also has a bronchodilating effect (229, 374) . Although the mechanisms underlying Mg 2ϩ -induced bronchodilation remain to be elucidated, Mg 2ϩ is known to inhibit the release of ACh and histamine, both known to induce bronchoconstriction (88, 291, 398, 427) . Moreover, Mg 2ϩ may reduce the airway inflammation that underlies several lung diseases, including chronic obstructive pulmonary disorder (COPD) and cystic fibrosis. In line with this, Mg 2ϩ deficiency has been reported in children with bronchitis, and low Mg 2ϩ levels can induce an inflammatory response in lung allografts (43, 440). Most of our understanding of the role of Mg 2ϩ in inflammation comes from studies in brain, heart, and intestine (450, 509, 553) , and only a few studies have examined the anti-inflamma- -treated patients compared with patients receiving ␤2-agonists (404). However, the patients covered by this systematic review were mainly adult patients. Recently, the outcomes of the MAGNEsium Trial In Children (MAGNETIC) randomized controlled study were published, showing improvement of the asthma severity score at 60 min (0.25, 95% CI 0.02-0.48) and 240 min (0.20, 95% CI 0.01-0.40) after inhalation of MgSO 4 (405) . The MAGNETIC study was not published at the time of the systematic reviews, and future analysis including this trial may further substantiate the beneficial effects of Mg 2ϩ in treatment of children with asthma.
Cystic fibrosis
Mg
2ϩ deficiency has been repeatedly reported in patients with cystic fibrosis (210, 380) . Patients with cystic fibrosis are often treated with recombinant human DNase-I to degrade the viscous mucus. However, the recombinant DNase requires Mg 2ϩ to function, and efficiency of the treatment depends, therefore, on the Mg 2ϩ status of the patient (444). It was suggested that Mg 2ϩ treatment in itself would be sufficient to trigger endogenous DNase activity in the sputum (426) . To further examine the potential role of Mg 2ϩ as treatment for cystic fibrosis patients, a small double-blind, randomized, placebo-controlled crossover study tested the effect of oral Mg 2ϩ supplementation on respiratory muscle strength and disease severity (444) . Patients supplemented with Mg 2ϩ increased their maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP). Although these first results are promising, more large-scale follow-up studies are necessary to assess the effects of Mg 2ϩ in cystic fibrosis patients.
COPD
Serum Mg
2ϩ levels have been associated with disease progression in patients with COPD (31, 46). Given the bronchodilating effects of Mg 2ϩ , several studies have examined whether intravenous or nebulized Mg 2ϩ may benefit COPD patients. In 1995, a small study of 27 COPD patients examined the effect of 1.2 g MgSO 4 infusion after ␤-agonist administration. Although the sample size was small, Mg 2ϩ -treated patients demonstrated higher peak expiratory flow values compared with placebo-treated patients (22 Ϯ 29 vs. 6 Ϯ 24%) (485) . In another small randomized double-blind controlled trial, Mg 2ϩ infusion resulted in improved functional respiratory capacity (Ϫ0.48 l, 95% CI: Ϫ0.96, Ϫ0.01), inspiratory capacity (0.21 l, 95% CI: 0.04 -0.37), MIP (10 cmH 2 O, 95% CI: 1.6 -18.4), and MEP (10.7 cmH 2 O, 95% CI: 0.20 -21.2) (123) . In contrast, a recent study using combined intravenous and nebulized MgSO 4 administration in 62 COPD patients did not detect significant effects on the primary outcome, as measured by hospital admission, intubation, and hospital death rates, nor did they find improved lung function (370) 
C. Magnesium in Heart and Vasculature
Mg 2ϩ plays an important role in heart function by influencing myocardial metabolism, Ca 2ϩ homeostasis, vascular The cardiac action potential consists of five phases: phase 0 is the rapid depolarization by the influx of Na ϩ . Phase 1 consists of rapid repolarization by efflux of K ϩ . Phase 2, named the plateau phase, is the longest phase and marks Ca 2ϩ entry. Phase 3 allows final repolarization of the cell by restoration of the membrane potential. Phase 4 is the stable phase with a resting potential of Ϯ90 mV (190) An important role of Mg 2ϩ in heart and vasculature function is a substantial vasodilatory effect that has been reported in animal and human studies (18, 161, 512, 513) . Although the results from animal studies suggest that Mg 2ϩ -induced vasodilation is due to the regulation of NO synthesis, human studies show that it is independent of NO activity (512, 513) . Moreover, Mg 2ϩ deficiency promotes oxidative stress notably in endothelial cells (118, 561) , resulting in increased reactive oxygen species (ROS) and cytotoxicity (590) . In contrast, high Mg 2ϩ in the cell increases eNOS activity and suppresses the synthesis of vasoconstrictor endothelin-1 (277, 327) . In conditions of low Mg 2ϩ -induced oxidative stress, the endothelium develops a state of permanent inflammation, which is marked by increased NFB activitiy (153) . NFB is the master regulator of transcription of cytokines and pro-inflammatorty genes, including IL-1␣. As a result of this local inflammation, the vessel wall will recruit monocytes and trigger the proliferation and migration of vascular smooth muscle cells. These processes are facilitated by the increased expression of matrix metalloproteases 2 and 9 in low Mg 2ϩ conditions (153, 382) . Eventually low Mg 2ϩ concentrations may, therefore, result in atherosclerosis, vascular calcifications, or thrombosis.
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tone, peripheral vascular resistance, and cardiac output. Mg 2ϩ exerts its effects in three ways: 1) Mg 2ϩ regulates the activity. Mg 2ϩ is mainly important in phases 2 and 3 of the myocardial action potential, exerting its effect on K ϩ and Ca 2ϩ channels. In phase 2
Coronary artery disease
Over the last 20 years, an increasing number of studies have demonstrated that low serum Mg 2ϩ levels and low Mg 2ϩ intake are associated with an increased risk of coronary artery disease (CAD), artherosclerosis, and metabolic syndrome (8, 222, 316, 587) . Low serum Mg 2ϩ levels have been associated with a higher mortality risk in CAD patients (162) . There may be several ways in which Mg 2ϩ supplementation benefits patients with CAD. Since Mg 2ϩ has a strong anti-inflammatory role, Mg 2ϩ results in an improved lipid profile, reduced free oxygen radicals, and improved endothelial function (317, 490) . Mg 2ϩ prevents blood clotting by reducing platelet aggregation (437) , and it has a strong vasodilator effect (512, 513) . These properties make Mg 2ϩ an important factor in the development and management of CAD. Mg 2ϩ improves several aspects of vascular function in CAD. Reduced serum Mg 2ϩ concentrations are associated with an increase in carotid intimamedia thickness and risk for sudden cardiac death (218, 324, 391) . In a randomized, double-blind, placebo-controlled study of 50 CAD patients, oral Mg 2ϩ supplementation ameliorated endothelial function (472) . Moreover, Mg 2ϩ reduced platelet-induced thrombosis in a randomized prospective, double-blind, crossover, and placebo-controlled study in 42 CAD patients (471) . Six months of Mg 2ϩ supplementation increased maximal oxygen uptake (V O 2 max ) and left ventricular ejection fraction (LVEF) in 53 CAD patients (401) . Taken together, these studies suggest that Mg 2ϩ levels should be closely monitored in CAD patients and propose Mg 2ϩ as potential drug to improve quality of life in CAD patients.
Myocardial infarction
In the 1970s, a pioneering paper by Abraham et al. (9) associated myocardial infarction with a significant drop in serum Mg 2ϩ . Indeed, low serum Mg 2ϩ levels have been associated with an increased risk of acute myocardial infarction (AMI) (484) . The role of Mg 2ϩ in preventing myocardial infarction may be caused by relaxing endothelial and smooth muscle cells in the heart and vasculature (18, 161, 512). Moreover, heart rate variability is a risk factor for AMI and Mg 2ϩ may prevent arrhythmia (474, 484) . Several studies have addressed the effect of Mg 2ϩ on myocardial infarction. In the 1980s, studies reported a 20% reduction of infarct size in Mg 2ϩ -treated patients, and decreased mortality after Mg 2ϩ infusion (352, 415) . Several follow-up studies suggested that decreased rates of arrhythmias after infarction explain the lower mortality (76, 487) . After these initial promising results, several clinical trials have addressed this subject. The Leicester Intravenous Magnesium Intervention Trial 2 (LIMIT-2) included 2,316 AMI patients and found 24% reduced mortality after 28 days in the Mg 2ϩ group (95% CI: 1-43%) (569). Moreover, two smaller studies by Shechter and colleagues reported reduced mortality rates of 50 and 40% (469, 470) . Contrary to these findings, in the fourth Infarct Survival and Magnesium in Coronies (ISIS-4) study, a randomized factorial trial in 58,050 patients showed no beneficial effects of intravenous Mg 2ϩ administration on survival (4). The results from the ISIS-4 study were called into question because the statistical analysis did not reflect the heterogeneous studies used in the analysis, the low mortality in the placebo-group was indicative of a low-risk comparison group, and the late time-point of Mg 2ϩ administration, namely, after and not during reperfusion, was at odds with animal data demonstrating the effectiveness of Mg 2ϩ (463) . However, also a second large-scale randomized double-blind study with 6,213 patients and an earlier time point of Mg 2ϩ infusion (3.8 h compared with 8 h in ISIS-4) also failed to show a decrease on 30-day mortality rates (2) . Indeed, a recent meta-analysis within the Cochrane collaboration concludes that there is no beneficial effect of Mg 2ϩ on mortality in AMI patients (OR 0.99, 95% CI 0.94 to 1.04) (312) . However, it should be noted that the ISIS-4 study provides 72% of the power in this analysis and that the Mg 2ϩ doses used within the analyzed studies differ significantly. Nevertheless, current guidelines do not recommend Mg 2ϩ administration in AMI patients.
Arrhythmia
In 1935, Dr. Zwillinger was the first to report an antiarrhythmic effect of Mg 2ϩ , and since then sporadic reports of patients treated with Mg 2ϩ have appeared in the literature (595) . However, the field suffers from a lack of largescale randomized controlled trials, and therefore the exact clinical benefit of Mg 2ϩ in treatment of arrhythmia remains to be determined. Mg 2ϩ is known to have a function in regulating cardiac K ϩ and Ca 2ϩ channels, so it affects the cardiac action potential. As a result, hypomagnesemia in itself has been proposed as a cause of arrhythmia, specifically in combination with stress or alcoholism (362, 524) . Clinical studies have demonstrated that treatment success strongly depends on the type of arrhythmia (232) . Atrial fibrillation is one of the most common and dangerous complications after cardiac surgery. In the last few decades, several small-scale studies have examined the effect of Mg 2ϩ in preventing these fibrillations (93) . Meta-analysis of these studies concluded that Mg 2ϩ infusion may prevent atrial fibrillations (201, 474) . Therefore, the European Association for Cardiothoracic Surgery and the Canadian Cardiovascular Society recommend prophylaxis with intravenous MgSO 4 . However, recent reports point to problems associated with many studies at the level of double-blinding, primary outcome, and intention-to-treat analysis. When only high quality studies are included, Mg 2ϩ does not have a preventive effect on atrial fibrillations (OR: 0.94, 95% CI: 0.61-1.44) (93) . A similar discrepancy between low-and high-quality studies has been noted for studies addressing the effects of Mg 2ϩ on supraventricular arrhythmias (108) . Interestingly, for treatment of torsades des pointes, Mg 2ϩ has been implemented as a first line of treatment after several studies in the 1980s showed beneficial effects (395, 527, 528) . However, due to the absence of large-scale clinical trials, optimal doses for treatment are still under debate (211, 243, 244) . Other arrhythmias, including refractory ventricular fibrillation and monomorphic ventricular tachycardia, are insensitive to Mg 2ϩ treatment (150, 220).
Preeclampsia
Since the 1950s, intravenous MgSO 4 administration has gradually become the standard treatment for preeclampsia and eclampsia, and nowadays the treatment is widely advocated by the World Health Organization (223, 407, 594) . The mechanisms of action underlying the effect of Mg 2ϩ in the treatment of these patients are largely unknown. Mg 2ϩ may reduce preeclampsia by its effect as vasodilator in the vasculature, but it cannot be excluded that Mg 2ϩ also functions as an anticonvulsant through blockade of the NMDA receptor and reduces cerebral edema (147) . Recent Cochrane systematic reviews showed that MgSO 4 treatment in preeclamptic women reduced the risk for eclampsia by Ͼ50% (RR 0.41, 95% CI 0.29 -0.58), and there was a trend towards lower maternal mortality (RR 0.54, 95% CI 0.26 -1.10) (130). MgSO 4 demonstrated similar ratios for reduced risk for eclamptic convulsions comparable to anticonvulsant medication, with 59% compared with diazepam (RR 0.41, 95% CI 0.29 -0.58) and 66% compared with phenytoin (RR 0.34, 95% CI 0.24 -0.49) (131, 132). Moreover, a recent meta-analysis of "real-world" use of MgSO 4 for the treatment of preeclampsia confirmed the results from the clinical trials and showed ϳ50% reduction of eclampsia risk in most studies (337) . Interestingly, although Mg 2ϩ was successful in preventing eclampsia, it did not change the risk of death or disability for children at 18 mo (RR 1.06, 95% CI 0.90 -1.25) or the risk of death or disability for women at 2 yr (RR 0.84, 95% CI 0.60 -1.18) (5, 6).
Hypertension
Low serum Mg 2ϩ levels are frequently linked to high blood pressure (30, 267, 270 (260, 275, 559) ; however, other studies fail to see such an effect (72, 152) . A systematic review of the Cochrane Hypertension Group reported a small reduction of diastolic blood pressure (DBP; Ϫ2.2 mmHg, 95% CI Ϫ3.4 to Ϫ0.9), but not of the systolic blood pressure (SBP; Ϫ1.3 mmHg, 95% CI Ϫ4.0 to 1.5) (119) . Another meta-analysis detected a small but dose-DE BAAIJ ET AL. dependent effect of Mg 2ϩ on blood pressure, for each 10 mmol/day Ϫ4.3 mmHg SBP (95% CI Ϫ6.3 to Ϫ2.2) and Ϫ2.3 mmHg DBP (95% CI Ϫ4.9 to 0.0) (262) . However, the outcomes may be biased by the inclusion of poor quality studies that tend to overestimate the effects. In contrast, a meta-analysis of a subset of studies, including patients on antihypertensive drugs with high blood pressure (SBP Ͼ155 mmHg) reports much stronger effects of oral Mg 2ϩ treatment on SBP (Ϫ18.7 mmHg, 95% CI Ϫ14.95 to Ϫ22.45) and DBP (Ϫ10.9 mmHg, 95% CI Ϫ8.73 to Ϫ13.1) (425). These results suggest that Mg 2ϩ may be beneficial for certain subgroups of hypertensive patients and that comparing the highly heterogeneous studies may underestimate the effects of Mg 2ϩ in these groups.
Vascular calcification
Vascular calcification is frequently observed in patients suffering from chronic kidney disease (CKD) (452) . Calcifications are a major contributor to cardiovascular death that accounts for 50% of all deaths in CKD (522) . Vascular calcification is the consequence of a disturbed mineral metabolism including increased serum P i levels. Increased serum levels of FGF23 and PTH enhance the formation of calicification. Low serum Mg 2ϩ levels are associated with vascular calcification, and hemodialysis patients with higher serum Mg 2ϩ levels show higher survival (258, 259) . Although the mechanisms of action are not completely understood, there are two contributing factors: 1) Mg 2ϩ prevents the formation and deposition of Ca/P nanocrystals and the development of appatite structures (83); and 2) Mg 2ϩ inhibits the transdifferentiation of the smooth muscle cells in the vessel well into osteoblast-like cells (282) . In both processes Mg 2ϩ prevents vascular calcifiction, and thus hypomagnesemic patients are at risk. Therefore, Mg 2ϩ supplementation has been proposed as P i -binder to reduce vascular calcification in CKD patients. Several studies have shown that combined administration of Ca 2ϩ and Mg 2ϩ is as effective as standard treatment options (252) . In the recent CALMAG study comparing MgCO 3 /Ca(OAc) 2 with Sevalamer-HCl in 200 hemodialysis patients, both treatments were effective in reducing serum P i levels without increasing Ca 2ϩ levels (106).
D. Magnesium in Muscle
Mg 2ϩ mainly exerts its effects on skeletal muscle function as a Ca 2ϩ antagonist on Ca 2ϩ -permeable channels and Ca 2ϩ -binding proteins. Muscle contraction is a highly Ca 2ϩ -dependent process, initiated Ca 2ϩ release from the sarcoplasmic reticulum. Ca 2ϩ binds to troponin C and myosin to induce the conformational changes of these proteins that will result in contraction (193 (584) . The role of Mg 2ϩ in the regulation of the Na ϩ -Ca 2ϩ exchanger (NCX) has been poorly studied so far.
Muscle cramps
Muscle cramps are a recurrent and prominent symptom in patients with severe/chronic hypomagnesemia (49, 215 (583) . Both meta-analyses are limited by a relatively small patient population. Large-scale studies are necessary to ascertain the utility of Mg 2ϩ for specific subpopulations or disease-related muscle cramps.
E. Magnesium in Pancreas
Mg 2ϩ has been implicated in both endocrine and exocrine functioning of the pancreas. In the pancreatic acini, intracellular Mg 2ϩ antagonizes Ca 2ϩ -activated signaling events and enzyme secretion (573) . It is known that ACh and cholecystokinin 8 (CCK8) evoke an increase in intracellular Ca 2ϩ , which in turn activates calmodulin, resulting in the phosphorylation of proteins on the enzyme-containing ves-
MAGNESIUM IN MAN
icles. These vesicles will migrate towards the plasma membrane for exocytosis and secretion. Interestingly, ACh and CCK8 activation cause a marked Mg 2ϩ efflux, allowing Ca 2ϩ signaling to occur (483, 564) . Its antagonizing role may be explained by inhibition of Ca 2ϩ transporting proteins such as SERCA, PMCA, and Ca ϩ -ATPases (120, 584) .
In the islets of Langerhans, Mg 2ϩ may influence the secretion of insulin, although experimental results are conflicting as to whether insulin secretion is increased or decreased. Milner and Hales (344) reported that Mg 2ϩ reduced insulin secretion in an ex vivo model using rabbit pancreas. These results were confirmed in rat pancreas and rat insulinoma cells (99, 357) . However, in rats, one study found increased insulin secretion in Mg 2ϩ -deficient rats, while other studies in Mg 2ϩ -deficient rats did not report alterations in plasma insulin concentrations (202, 338, 418) . In addition, patients with low serum Mg 2ϩ levels show decreased insulin secretion (422 
Diabetes
Patients with diabetes mellitus type 2 often have low serum Mg 2ϩ levels (36, 491, 541). These low serum levels are associated with poor disease outcome and may even increase mortality (98) . Hypomagnesemia may contribute to the development of diabetes mellitus type 2 by increasing insulin resistance. Insulin receptors (IR) are part of the family of tyrosine kinase receptors, and the kinase function is dependent on the binding of two Mg 2ϩ ions (249) . Upon activation of the IR, a complex intracellular signaling cascade is activated and mediated via insulin receptor substrate proteins (505) . In low Mg 2ϩ conditions, activation of the IR may result in diminished signal transduction, contributing to insulin resistance. Studies with hypomagnesemic rats bear this out, as lower IR phosphorylation was detected, although differences between individual organs were reported (419, 498) . It has also been proposed that increased expression of other effectors such as IL-1, IL-6, IL-8, TNF-␣, norepinephrine, epinephrine, and ROS may contribute to insulin resistance in Mg 2ϩ deficiency (206). Interestingly, common SNPs in the TRPM6 gene are associated with an increased risk of developing diabetes mellitus type 2 (489). TRPM6 cannot be activated by insulin when these SNPs are present (361) . These results suggest that Mg 2ϩ levels may influence the onset and development of diabetes mellitus type 2. Several studies have examined the clinical effects of oral Mg 2ϩ supplementation on glycemic control in diabetes mellitus type 2 patients. Some of these studies demonstrate impressive effects in reducing glucated hemoglobin (HbA 1c ) levels and fasting glucose concentrations (385, 423) , but other studies show no improvement of glycemic control (107, 204) . A meta-analysis of 8 studies, including a total of 370 patients, evidenced a reduction of fasting glucose levels (Ϫ0.56 mM; 95% CI, Ϫ1.10 to Ϫ0.01), reflected in a nonsignificant (P ϭ 0.1) reduction of HbA 1c levels (Ϫ0.31%, 95% CI, Ϫ0.81 to 0.19) (488) . All together, these results indicate that Mg 2ϩ supplementation may be a promising avenue for achieving glycemic control in diabetes patients.
F. Magnesium in Liver
The role of Mg 2ϩ in the liver is poorly studied. However, given that many of the enzymatic reactions that take place in the hepatocytes are dependent on Mg 2ϩ , particularly in fat metabolism, the importance of Mg 2ϩ should not be underestimated. Mg 2ϩ supplementation has been reported to reduce alanine aminotranferase (ALT) levels in obese women with hypomagnesemia (421). However, this result could not be reproduced in normomagnesemic patients, although a lower dose of Mg 2ϩ was used in this study (271) . The first reports of hypomagnesemia in liver diseases such as cirrhosis and nonalcoholic fatty liver disease suggest that liver function contributes to proper intestinal Mg 2ϩ absorption (286, 526) . Currently, the first clinical trials are being initiated to test the effects of Mg 2ϩ supplementation in patients with liver cirrhosis.
G. Magnesium in Immunity
Mg 2ϩ is considered as an anti-inflammatory agent that reduces the expression and release of substance P and other proinflammatory molecules. Mg 2ϩ also influences acquired immunity by regulating the proliferation and development of lymphocytes (156) . Deletion of the TRPM7 Mg 2ϩ channel caused cell death in the chicken B cell line DT40, which could be partially rescued by culturing the cells in high Mg 2ϩ containing medium (455) . In a mouse model with a specific T-cell deletion of TRPM7, T lymphocyte development was blocked at the CD4 Ϫ
CD8
Ϫ stage, resulting in decreased CD4
ϩ and CD4 ϩ CD8 ϩ cells in the thymus (266) . Moreover, mutations in the MagT1 Mg 2ϩ channel are causative for immunodeficiency and have been associated with decreased CD4 ϩ T lymphocyte levels (311). These results suggest that Mg 2ϩ is essential for T lymphocyte development and proliferation.
X-linked T-cell immunodeficiency
Patients with X-linked immunodeficiency with Mg 2ϩ defect, Epstein-Barr virus infection and neoplasia (XMEN) have mutations in MagT1 (79, 311) . They present with chronic Epstein-Barr virus infections, low CD4 ϩ T-cell counts, and defective T-lymphocyte activation. These effects are hypothesized to result from a loss of PLC␥1 activation due to reduced Mg 2ϩ influx via MagT1 (311) . Recent studies in asthma pa-tients confirm the importance of Mg 2ϩ availability for CD4 ϩ function (315) . An increased risk in T-cell lymphoblastic leukemia has been associated with Mg 2ϩ deficiency (441) . However, the role of Mg 2ϩ in T-cell signaling needs to be investigated before further conclusions can be drawn. Special attention should be given to the involvement of other Mg 2ϩ carriers, since TRPM7-deficient T cells seem protected from Fas-receptor-induced apoptosis (115) .
H. Magnesium in Bone
Bone hydroxyapatite structures mainly consist of P i and Ca 2ϩ and are bound by Mg 2ϩ ions at the surface of the hydroxyapatite crystals. Mg 2ϩ increases the solubility of the minerals and thereby acts on the crystal size and formation (443) . Crystals in Mg 2ϩ -deficient bone are larger, and the bone may therefore be brittle and more susceptible to fractures (89) . Moreover, Mg 2ϩ stimulates osteoblast proliferation, suggesting that Mg 2ϩ deficiency results in decreased bone formation (320) (FIGURE 4). The role of bone in Mg 2ϩ homeostasis is described in more detail in section IIIB.
Osteoporosis
Several studies have associated low serum Mg 2ϩ values with osteoporosis (61, 213). Although most studies have been performed in postmenopausal women, there is some evidence of low bone Mg 2ϩ content in elderly subjects. In this study the patients had normal serum Mg 2ϩ levels, but displayed significantly increased retention in a loading/tolerance test (91) . A few small-scale studies have examined the effects of oral Mg 2ϩ supplementation (200 -750 mg/day) on bone mineral density (BMD) in patients with osteoporosis. In a pioneering study in 1991, daily administration of 600 mg Mg resulted in an 11% increased BMD after 12 mo (10). However, many other supplements including 500 mg/day Ca were simultaneously used, making it difficult to distinguish the effects of Mg 2ϩ . Subsequently, multiple studies have examined the effect of Mg 2ϩ supplementation in different populations (138, 436, 494) . Mg 2ϩ seems to increase BMD in all of the studies, although the effects are relatively small (1-3%) and the small study sizes limit the conclusions that can be made from them. Testing the effect of Mg 2ϩ supplementation in large cohorts of osteoporosis patients may further establish Mg 2ϩ supplements to treat osteoporosis.
V. DISTURBANCES OF MAGNESIUM HOMEOSTASIS
Over the last decade, clinical interest in Mg 2ϩ has been growing. Mg 2ϩ deficiency has been associated with a wide range of diseases including diabetes mellitus type 2, hypertension, migraine, and depression. Therefore, the Mg 2ϩ balance in patients is clinically significant; however, Mg 2ϩ status in patients is not routinely determined. When Mg 2ϩ is assessed in pa- However, serum Mg 2ϩ levels represent Ͻ1% of the body Mg 2ϩ content, and therefore, it is a poor predictor of the body Mg 2ϩ status. Additionally, the Mg 2ϩ concentration in red blood cells is higher than in the serum (1.65-2.65 mM) , and extra care should be taken to prevent hemolysis, which can result in a misrepresentation of total serum Mg 2ϩ (520) . In a recent systematic review, red blood cell (RBC) Mg 2ϩ content has been proposed as an alternative measure to determine Mg 2ϩ status, since its value is strongly affected by alterations in dietary Mg 2ϩ intake in six studies (n ϭ 130) (565 , which is more sensitive than serum Mg 2ϩ concentrations. However, this test is rarely used in clinic, and as a result, standardization is lacking. Within a research setting, a urine excretion of Ͻ60% of the Mg 2ϩ load is generally considered normal.
If a Mg 2ϩ disturbance is suspected, urinary Mg 2ϩ concentrations are regularly determined. It should be noted that reliable urine Mg 2ϩ determinations require at least a complete 24-h sampling, since the circadian rhythm influences renal Mg 2ϩ excretion (158) . The results of urine Mg 2ϩ tests may provide information about the cause of Mg 2ϩ deficiencies; normal or high urinary excretion indicates renal Mg 2ϩ wasting, whereas low Mg 2ϩ excretion suggests reduced intestinal absorption. This information can then be used to guide treatment plans.
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kidney function is reduced. In several pathophysiological circumstances such as diabetes and chronic kidney disease, filtration may be altered. Additionally, the use of certain drugs including diuretics may cause bias in determining a patient's Mg 2ϩ status.
A. Hypermagnesemia
Serum Mg 2ϩ levels above 1.1 mM are generally considered hypermagnesemic. Hypermagnesemia may be clinically observed in patients suffering from nausea, vomiting, lethargy, headaches, and/or flushing. When Mg 2ϩ levels rise above 3.0 mM it may even cause severe cardiac defects that are characterized by brachycardia, hypotension, and prolongation of the QRS, PR, and QT intervals (TABLE 3) . Extreme hypermagnesemia can therefore result in coma, asystole, and death by cardiac arrest. However, hypermagnesemia is rare and until now no genetic causes for it have been identified. Hypermagnesemic patients are often treated by infusion of Ca 2ϩ salts to antagonize the cardiac effects of Mg 2ϩ (433) . Also the efficacy of hemodialysis in the treatment of acute hypermagnesemia has been illustrated (228, 379).
Drug-induced hypermagnesemia
Only a few drug-induced cases of hypermagnesemia have been reported, and most of them are the direct consequence of the administration of Mg 2ϩ itself or Mg 2ϩ -containing drugs (TABLE 4) .
A) EPSOM SALTS. Epsom salts consist of MgSO 4 and are generally used as bath salts or a home remedy against abdominal pain, constipation, and muscle strains. Excessive ingestion of Epsom salts may result in Mg 2ϩ overdose and hypermagnesemia. As a result, several fatal cases have been reported in literature (52, 231) 2ϩ substances elevate the intestinal osmotic pressure, but also act on aquaporin-3 expression and thus increase water permeability (373) . Mg 2ϩ has been used as a component of enemas to treat constipation. However, both use of Mg 2ϩ as a laxative and as an enema may result in fatal hypermagnesemia (413, 521, 586) . Therefore, Mg 2ϩ administration should be avoided in patients with reduced kidney function, and serum Mg 2ϩ should be closely monitored during treatment.
B. Hypomagnesemia
Hypomagnesemia is generally defined as serum Mg 2ϩ levels below 0.7 mM. Patients suffer from nonspecific symptoms such as depression, tiredness, muscle spasms, and muscle weakness, and diagnosis therefore may take years (TABLE 3) (177, 523) . Only severe Mg 2ϩ depletion (Ͻ0.4 mM) may lead to cardiac arrhythmias, tetany, and seizures. Secondary to hypomagnesemia, disturbances in K ϩ and Ca 2ϩ handling are often detected. Hypokalemia can be attributed to increased renal K ϩ secretion via ROMK in the connecting tubule (CNT) and collecting duct (CD) (248) . Low intracellular Mg 2ϩ levels release the Mg 2ϩ -dependent inhibition of ROMK channels, resulting in increased renal K ϩ secretion. Hypocalcemia can be explained by low PTH levels due to altered activation of the CaSR (574).
Hypomagnesemia is generally treated by oral Mg 2ϩ supplementation (Ϯ360 mg/day), although oral Mg 2ϩ intake may cause diarrhea at high doses. Intravenous Mg 2ϩ supplementation may be more effective, but this treatment has the disadvantage that it requires regular hospital visits. The treatment regimen of intravenous Mg 2ϩ supplementation normally consists of 8 -12 g of magnesium sulfate in the first 24 h followed by 4 -6 g/day for 3 or 4 days (523). When serum Mg 2ϩ levels are extremely low or are accompanied by hypokalemia, Mg 2ϩ supplementation may not be sufficient to restore normal Mg 2ϩ levels. In that case, patients are often cosupplemented with K ϩ or receive amiloride to prevent K ϩ secretion.
The following section of this review will focus on the causes of hypomagnesemia. Drug-induced and genetic hypomagnesemia will be distinhished from more general origins of Mg 2ϩ deficiency (TABLES 4 AND 5). nuts, green vegetables, and whole grains may prevent this. However, insufficient Mg 2ϩ intake may also be caused by pathological conditions such as anorexia nervosa (51). B) VOMITING AND DIARRHEA. Vomiting and diarrhea may further exacerbate the effects of inadequate Mg 2ϩ uptake. Specifically, diarrhea is the consequence of inadequate water reabsorption along the intestine. Since water reabsorption is a prerequisite for Mg 2ϩ reabsorption to set the concentration gradient, diarrhea may result in Mg 2ϩ deficiency.
General causes of hypomagnesemia
C) ALCOHOLISM. Since the early 1960s it has been recognized that alcoholism may cause severe hypomagnesemia (224, 336) . Patients suffer from unexplained renal Mg 2ϩ wasting, but may also have reduced intestinal Mg 2ϩ absorption due to vomiting or diarrhea. In hepatocytes, ethanol completely blocked Mg 2ϩ uptake (75) . A similar mechanism may take place in the kidney, explaining reduced Mg 2ϩ reabsorption. Alcoholics often have reduced PTH levels, which may further contribute to low serum Mg 2ϩ levels (7). 
Genetic hypomagnesemia
A) CLDN16. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis type I (FHHNC type I; OMIM 248250) is caused by mutations in claudin 16, previously known as paracellin-1 (480) . Patients suffer from renal Mg 2ϩ wasting, hypomagnesemia, renal Ca 2ϩ wasting, renal parenchymal calcification (nephrocalcinosis), and renal failure. Serum and urinary Na ϩ , K ϩ , Cl Ϫ , and HCO 3 Ϫ values are initially normal, but may be indirectly affected after progression of renal failure. Sometimes these symptoms are extended to urinary tract infections, kidney stones, and hyperuricemia; Mg 2ϩ supplementation is not capable of restoring normal serum Mg 2ϩ levels or slowing disease progression (567) . A few dozen different mutations have been reported, all characterized by a recessive mode of inheri- tance (177) . All symptoms can be traced to the TAL, the main site for paracellular Ca 2ϩ and Mg 2ϩ reabsorption. Claudin 16 is part of the tight junction between the cells, and disruption of these tight junctions results in a lack of Ca 2ϩ and Mg 2ϩ reabsorption in TAL, which can only partially be compensated in the downstream DCT and CNT segments. B) CLDN19. Similar to FHHNC type I, patients with FHHNC type 2 (OMIM 248190) suffer from severe hypomagnesemia accompanied by hypercalciuria and nephrocalcinosis. Additionally, patients have ocular defects consisting of macular colobomata, significant myopia, and horizontal nystagmus. FHHNC type 2 is caused by mutations in claudin 19, which is expressed in the TAL segment of the kidney, in parallel with claudin 16. In the initial publication from Konrad et al. (293), 12 patients from 10 families were genotyped and characterized. Remarkably, 9 of 12 patients developed chronic kidney disease or underwent kidney transplantation. Indeed, other studies confirmed that FHHNC type 2 patients are more prone to developing of CKD and develop the disease at an earlier age compared with type I patients (177) . Over the years, several treatment regimens have been proposed, including oral magnesium supplementation, thiazide diuretics, and indomethacin. However, none of these treatments significantly increased serum Mg 2ϩ values (177).
C) TRPM6. Hypomagnesemia with secondary hypocalcemia (HSH; OMIM 602014) is characterized by extremely low serum Mg 2ϩ levels (0.1-0.3 mM) accompanied by low serum Ca 2ϩ levels, which result in severe muscular and neurological complications including seizures and mental retardation (454, 543) . The disorder was first characterized by Paunier and colleagues in 1968 and later mapped to a region at chromosome 9q in 1997 (390, 544) . In 2002, two independent groups identified mutations in TRPM6 to be causative for HSH (454, 543 (197) . In a consanguine family from Dutch origin, two sisters presented with serum Mg 2ϩ levels of 0.53 and 0.56 mM and urinary Mg 2ϩ values of 3.9 and 3.7 mmol/24 h, respectively (173) . Serum Ca 2ϩ , Na ϩ , K ϩ , Cl Ϫ , HCO 3 Ϫ , and blood pH values were normal. The patients presented with epileptic seizures during their first year of life, which could be controlled by antiepileptic drugs. Moreover, psychomotor retardation was observed in these patients. Plasma renin activity, plasma aldosterone, and parathyroid hormone concentrations were in the normal range. Homozygosity mapping and subsequent Sanger sequencing of gene candidates led to the identification of a homozygous c.C3209T mutation in exon 22 resulting a p.P1070L missense mutation at protein level (197) . This residue is particularly important for plasma membrane targeting of the EGF molecule and the mutation results in impaired basolateral sorting of pro-EGF. Therefore, TRPM6 activity is not stimulated, resulting in renal Mg 2ϩ wasting (197, 515) . Until now, only a single family has been described with EGF mutations, but studies with EGFR antagonists further underline the clinical importance of EGF for renal Mg 2ϩ handling (discussed in detail in sect. VB3). excretion were within normal range. KCNA1 mutations were previously linked to ataxia and myokymia (62, 146). Therefore, a cerebral MRI was performed in these patients, showing slight atrophy of the cerebral vermis. Family members suffer from myokymic discharge in electromyograph analysis, which is in line with the previously observed mixed phenotype. Intravenous Mg 2ϩ infusion improved the clinical symptoms. Kv1.1 has been proposed to cause apical hyperpolarization, which allows the uptake of Mg 2ϩ via TRPM6. The p.N255D (c.A763G) mutation identified in the Brazilian family disrupts Kv1.1 activity and therefore may reduce the driving force for Mg 2ϩ transport. Although many KCNA1 mutations have been reported, even in residues very close to the p.N255, none of these has yet been associated with hypomagnesemia, even though Kv1.1 function is impaired (12, 263) . Identification of additional hypomagnesemic families with Kv1.1 mutations may aid our understanding of Kv1.1 function in DCT. It has been suggested that other factors contribute to the apical membrane potential and may compensate for a loss of Kv1.1 function; ROMK may be one of the compensatory factors (104, 140) . F) CNNM2. Mutations in CNNM2 are causative for hypomagnesemia with seizures and mental retardation (HSMR; OMIM 613882). Two unrelated families with seizures and dominant hypomagnesemia were reported to carry CNNM2 mutations (497) . In these patients, serum Mg 2ϩ levels range between 0.3 and 0.5 mM, but no other electrolyte disturbances were detected. The patients' symptoms
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include seizures, loss of consciousness, loss of muscle tone, headaches, and staring (340) . Recently, five additional families were reported (28), making CNNM2 the most common genetic cause of isolated hypomagnesemia after TRPM6 and CLDN16 -19. Interestingly, in this new cohort CNNM2 mutations were linked to a phenotype of impaired brain development and mental retardation. This intellectual disability was most prominent in a family with a recessive pattern of inheritance, emphasizing the heterogeneous inheritance of CNNM2 depending on the location and severity of the mutations. wasting. In some patients, high renin and aldosterone levels, salt craving, and polyuria were observed. Kir4.1 is hypothesized to be involved in K ϩ recycling at the basolateral membrane of DCT cells. When Kir4.1 is mutated, K ϩ availability becomes rate limiting for Na ϩ -K ϩ -ATPase activity. Thus the Na ϩ -K ϩ -ATPase will be inhibited, resulting in a reduced potential across the basolateral membrane. Consequently, Na ϩ and Mg 2ϩ transport will be reduced in DCT. To compensate for this, ENaC activity in CNT will be increased at the expense of K ϩ excretion via ROMK. Therefore, SeSAME/EAST patients suffer from severe hypomagnesemia and hypokalemia. To treat the hypomagnesemia, patients are often given Mg 2ϩ and K ϩ supplements, in combination with aldosterone antagonists or ENaC inhibitors (34). SeSAME/EAST patients suffer from a severe neurological phenotype consisting of tonic-clonic seizures in infancy, cerebellar ataxia, and hearing loss. Moreover, magnetic resonance imaging evidenced subtle symmetrical signal changes in the cerebellar dentate nuclei (96 , Cl Ϫ , and HCO 3 Ϫ , were normal. Urinary Mg 2ϩ excretion was increased, whereas Ca 2ϩ excretion was slightly lowered (172) . The c.G121A mutation results in a p.G41R missense mutation at the protein level, which causes misrouting of FXYD2 to the membrane (66) . FXYD2 encodes for the ␥-subunit of the Na ϩ -K ϩ -ATPase. Although the exact role of FXYD2 in the DCT is unknown, it has been hypothesized to stabilize the Na ϩ -K ϩ -ATPase, influencing the membrane potential necessary for Mg 2ϩ transport (345) . However, other reports suggest that it may function independently as an inward rectifier channel (464) . Functional analysis of the patient's proximal tubular cells showed no differences in Na ϩ , K ϩ , or ATP affinity of the Na ϩ -K ϩ -ATPase, but demonstrated a lower FXYD2 protein expression (67) . I) HNF1B. Renal cysts and diabetes syndrome (RCAD; OMIM 137920) is caused by mutations in hepatocyte nuclear factor 1␤ (HNF1␤) and consists of a heterogeneous group of symptoms including renal cysts (Ϯ70% of patients), maturity onset diabetes of the young subtype 5 (MODY5; Ϯ50%), and hypomagnesemia (Ϯ45%) (11, 82) . HNF1␤ is a transcription factor regulating gene expression in kidney development (331) . FXYD2b expression is one of several genes that is regulated by HNF1␤ (155) , which may explain its role in renal Mg 2ϩ handling. However, the possibility that HNF1␤ regulates other DCT genes involved in renal Mg 2ϩ transport cannot be excluded.
J) PCBD1. In a small cohort of three patients, mutations in pterin-4 ␣-carbinolamine dehydratase 1 (PCBD1) have been linked to hypomagnesemia, renal Mg 2ϩ wasting, and MODY5-like diabetes (154) . PCBD1 mutations are known to cause transient neonatal hyperphenyalaninemia and high urinary levels of primapterin (HPABH4D; OMIM 264070) (518, 519) . HPABH4D patients are diagnosed at birth by Guthrie testing and suffer from a transient, benign defect in impaired BH4 regeneration. A follow-up study of three patients at Ϯ18 yr of age showed that the patients display a mild hypomagnesemia (Ϯ0.6 mM) and MODY5-like diabetes, but no renal cysts (154) . Interestingly, serum and urinary Na
, and Cl Ϫ levels were within the normal range. The phenotype of the HPABH4D patients resembles that of RCAD patients, and the treatment regime consists of sulfonylureas and Mg 2ϩ supplements. The origin of renal cysts in RCAD patients may be traced to the CD where HNF1␤ regulates PKHD1 (194) . However, since PCBD1 is not expressed in CD, HPABH4D patients are protected from cyst formation (154). K) SLC12A3. Hypomagnesemia and hypokalemia are the cardinal symptoms of a hereditary electrolyte disorder characterized by Dr. Gitelman in 1969 that has been known since as Gitelman's syndrome (175) . Patients present with tetany, paresthesias, and chondrocalcinosis (284) . The severity of the symptoms depends on the degree of hypokalemia. Except hypokalemia and hypomagnesemia, laboratory inves-tigations often show metabolic alkalosis and hypocalciuria, sometimes associated with a mild hypotension and prolonged QT interval. SLC12A3 encodes the thiazide-sensitive Na ϩ -Cl Ϫ cotransporter (NCC), and mutations here cause Gitelman's syndrome (165, 481) . Patients with Gitelman's syndrome are often treated with oral Mg 2ϩ supplements (284) . Interestingly, in some patients Mg 2ϩ supplementation restores normal K ϩ levels, suggesting that hypokalemia is secondary to hypomagnesemia (205) . This hypothesis is further substantiated by the NCC KO mouse, which is hypomagnesemic but does not display K ϩ disturbances under basal conditions (460) . NCC KO mice have markedly reduced TRPM6 expression levels, possibly explaining the renal Mg 2ϩ wasting observed in Gitelman's syndrome (368) . However, the mechanism by which a loss of NCC function results in reduced TRPM6 expression remains unresolved. It has been suggested that the atrophy of the DCT segment observed in KO mice may partially explain this phenomenon (321). L) SLC12A1, BSND, CLCNKB, AND KCNJ1. Bartter's syndrome was originally described by Dr. Bartter in 1962 and is characterized by salt wasting, hypokalemic alkalosis, elevated plasma renin and aldosterone levels, and low blood pressure (40). Mutations in SLC12A1, encoding NKCC2, Barttin, ClC-Kb, KCNJ1, encoding ROMK, or CaSR form the genetic basis of Bartter's syndrome (50, [477] [478] [479] . Mild hypomagnesemia is sometimes observed in Bartter's patients, which may be explained by a reduced driving force for paracellular Mg 2ϩ reabsorption in the TAL. Compensation for reduced TAL Mg 2ϩ reabsorption may take place in the DCT, which explains why Bartter's patients often have normal Mg 2ϩ levels. ClC-Kb and Barttin are also expressed in DCT, which justifies why patients with mutations in these genes more often show hypomagnesemia (261). wasting as a consequence of furosemide treatment. Furosemide inhibits the activity of NKCC2, reducing the positive transepithelial membrane potential that drives paracellular Mg 2ϩ transport in TAL (408) . Although the incidence of furosemide-induced hypomagnesemia is unclear, a significant number of patients who use it may suffer from Mg 2ϩ wasting (92, 330) . In a recent animal study, furosemide treatment did not result in hypomagnesemia since increased TRPM6 expression in the DCT was able to compensate for reduced Mg 2ϩ reabsorption in TAL (530) . The clinical effects of furosemide treatment on Mg 2ϩ levels may, therefore, depend on the individual's ability to compensate at DCT level.
Drug-induced hypomagnesemia
The use of thiazide diuretics, which target NCC in DCT, frequently induces renal Mg 2ϩ wasting (366) . Although most studies do not report hypomagnesemia in patients being treated with thiazide diuretics, some patient groups may be at risk (101 (300) . Therefore, it was hypothesized that omeprazole may inhibit the activity of the colonic H ϩ -K ϩ -ATPase, resulting in reduced extrusion of protons into the colon. Since TRPM6 activity increases at lower external pH, decreased proton secretion may reduce TRPM6 activity, for which increased TRPM6 expression may compensate (300, 313) . However, increased TRPM6 expression may not be sufficient to prevent malabsorption of Mg 2ϩ in colon in all patients. Individual variability of this compensatory mechanism may explain why only a subset of PPI users develop hypomagnesemia. E) CISPLATIN/CARBOPLATIN. Already from the introduction of cisplatin (cis-diamminedichloridoplatinum) as anti-cancer therapeutic, hypomagnesemia has been reported in ϳ40%-80% of treated patients (453, 593) . Nephrotoxicity is a common side effect of cisplatin treatment, mainly as a consequence of proximal tubule cisplatin accumulation, which results in necrosis of the tubular cells (298) . However, the effect of cisplatin on electrolyte wasting is highly specific for Mg 2ϩ ; concomitant Ca 2ϩ and K ϩ wasting is only observed in severely hypomagnesemic patients. This suggests that hypomagnesemia cannot be explained by the nephrotoxictiy and that Ca 2ϩ and K ϩ disturbances are secondary to Mg 2ϩ wasting. Treatment with carboplatin [paraplatin, cisdiammine(1,1-cyclobutanedicarboxylato)platinum], another platinum derivate, results in similar side effects including hypomagnesemia (142, 495) . Recently, two animal studies have examined the effects of cisplatin treatment in detail (305, 529) . Both observe significant downregulation of TRPM6 mRNA levels, although the causative mechanisms of reduced TRPM6 expression may differ. In the mice study of Van Angelen et al. (529) , all DCT markers including parvalbumin and NCC are reduced, suggesting that cisplatin treatment induced atrophy of the DCT segment. In rats, Ledeganck et al. (305) (167, 446) . In a recent study with gentamycin-treated rats, TRPM6 expression was upregulated, suggesting that the DCT compensates for reduced TAL Mg 2ϩ reabsorption (307).
Pentamidine is an antimicrobial against Pneumocystis jirovecii infections that are often diagnosed in AIDS patients. The use of pentamidine has been associated with severe hypomagnesemia due to renal Mg 2ϩ wasting at the start of the 1990s (65, 188, 465) . The exact mechanism of reduced Mg 2ϩ reabsorption remains unresolved. However, pentamidine reduces ENaC activity, resulting in hyperkalemia (283) . Moreover, there have been reports of tubular necrosis after pentamidine treatment (546) , which may cause atrophy of the DCT segment.
Rapamycin (sirolimus) is an antibiotic that is frequently used to prevent organ rejection after transplantation. Rapamycin inhibits mTOR activity, and its use has been associated with hypomagnesemia in 10 -25% of patients (23, 535). Rapamycin-treated rats exhibit reduced expression of NKCC2 (100). Interestingly, TRPM6 expression was increased in the same study. This could be compensation for the reduced Mg 2ϩ uptake in TAL, but a direct effect of rapamycin on TRPM6 expression cannot be excluded. A recent in vitro study showed the opposite effect; rapamycin decreased TRPM6 expression in an EGF-dependent manner (255).
Amphotericin B is an antifungal agent that has been associated with hypomagnesemia and hypokalemia (38). The mechanism underlying urinary Mg 2ϩ wasting in these patients is unknown. Oral Mg 2ϩ supplementation together with amiloride treatment is generally used to restore Mg 2ϩ levels (178) .
Foscarnet inhibits viral DNA polymerases by chelating divalent cations and, therefore, its use may cause hypomagnesemia (169) . Patients also suffer from hypocalcemia and DE BAAIJ ET AL.
hypokalemia, which may be secondary to the Mg 2ϩ disturbances (253, 369) . Until now, no studies have examined the effect of forscarnet on the expression of renal ion transporters. It would be interesting to examine whether forscarnet exhibits effects beyond its chelating function. Genetic and drug-induced disorders of Mg 2ϩ homeostasis have enhanced the knowledge on Mg 2ϩ (re)absorption in the kidney and intestine. These studies form a perfect example of the powerful interaction of clinical and fundamental studies. For instance, the increased knowledge on the role of EGF in renal Mg 2ϩ handling has resulted in the standardization of Mg 2ϩ measurements in patients using EGFR blockers. This resulted in early detection of Mg 2ϩ disturbances and changes in treatment strategies. Through synergistic clinical and fundamental efforts in the fields of brain, heart, and lung Mg 2ϩ research, the unexplained role of Mg 2ϩ in, among others, migraine, depression, epilepsy, COPD, and hypertension, may be elucidated. Over the last decades Mg 2ϩ research has been centered around the kidney and the intestine. By extending the field to the heart, brain, and lungs and by involving both fundamental and clinical researchers, Mg 2ϩ will never be thought of as "a forgotten cation" anymore. 29. Asai T, Nakatani T, Yamanaka S, Tamada S, Kishimoto T, Tashiro K, Nakao T, Okamura M, Kim S, Iwao H, Miura K. Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism. 
VI. CONCLUDING REMARKS
